

10-12-00

A

VIA EXPRESS MAIL NO. EL629423599US

DATE OF DEPOSIT: October 10, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
UNDER 35 CFR 1.53(b)

|  |   |   |                   |
|--|---|---|-------------------|
| Docket No:<br>600-1-087CIP/<br>DIV/CON | Anticipated Classification<br>of this Application:<br>Class      Subclass | Prior Application:<br>600-1-087CIP/DIV<br>Examiner: Yucel, I. | Art Unit:<br>1636 |
|--|---|---|-------------------|

Address to: BOX PATENT APPLICATION  
ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Sir:

This is a Request for Filing a ☒ Continuation ☐ Divisional Application under 37 CFR 1.53(b) of pending Application Serial No. 09/183,374, filed on October 30, 1998, of Jeffrey Friedman et al., for MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF.

1. ☒ Enclosed is a copy of the prior application, including the oath or declaration as originally filed and an affidavit or declaration verifying it as a true copy.
2. ☐ Prepare a copy of the prior application.
- 3.a. ☐ This is an application of a small entity under 37 CFR 1.9(f), and the amounts shown below in parentheses apply. A copy of the verified statement(s) filed in the prior application is enclosed.
- b. ☐ The Filing Fee is calculated below:

| FOR:  | NO. FILED | NO. EXTRA | RATE          | BASIC FEE |
|---|-----------|-----------|---------------|-----------|
| BASIC FEE   |           |           |               | \$ 760.00 |
| TOTAL CLAIMS  | -20=      | 0         | X\$18 (\$9)   |           |
| INDEP. CLAIMS   | -3=       | 0         | X\$82(\$41)   |           |
| TOTAL FILING FEE  |           |           |               | \$        |
| <input type="checkbox"/> MULTIPLE DEPENDENT CLAIM(S)<br>PRESENTED (IF APPLICABLE)   |           |           | X\$260(\$130) |           |
| TOTAL OF ABOVE CALCULATIONS   |           |           |               | \$        |
| Reduction by 1/2 for filing by Small Entity (Note: 37 CFR 1.3, 1.27, 1.28). If applicable, verified statement must be attached. |           |           |               |           |
| TOTAL   |           |           |               | \$        |

4. ☒ The Commissioner is hereby authorized to charge any fees which may be required in addition to those calculated above, or credit any overpayment to Deposit Account No. 11-1153.

DATE OF DEPOSIT: October 10, 2000

5. ☐ A check in the amount of \$\_\_\_\_\_ is enclosed.
6. ☐ Cancel in this application original Claims \_\_\_\_\_ of the prior application before calculating the Filing Fee.
7. ☒ Amend the specification by inserting before the first line the sentence:  
This Application is a ☒ Continuation ☐ Division, of Application Serial No. 09/183,374 filed on October 30, 1998.
8. ☐ Transfer the drawings from the prior application to this application and abandon said prior application as of the Filing Date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
9. ☐ New Drawings are enclosed, seven ( ) Sheets, Figures \_\_\_\_\_.
10. ☐ Priority of Application Serial No. \_\_\_\_\_, filed on \_\_\_\_\_ in \_\_\_\_\_ is claimed under 35 U.S.C. §119.
11. ☐ The certified copy has been filed in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.
12. ☒ The prior application is assigned of record to The Rockefeller University recorded on November 13, 1995, at Reel 7718/Frame 0306.
13. ☒ The power of attorney in the prior application is to:  
Jack Matalon (Attorney, Registration No. 22,441); Stefan J. Klauber (Attorney, Registration No. 22,604); David A. Jackson (Attorney, Registration No. 26,742); Barbara L. Renda (Attorney, Registration No. 27,626); Raymond M. Speer (Attorney, Registration No. 26,810); Paul F. Fehlner (Attorney, Registration No. 35, 135); and Joseph M. Homa (Attorney, Registration No. 40,023).
- a. ☒ The power appears in the original papers in the prior application.
- b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. ☒ Address all future communications to:  
David A. Jackson, Esq.  
KLAUBER & JACKSON  
411 Hackensack Avenue  
Hackensack, New Jersey 07601.
14. ☐ A Preliminary Amendment is enclosed. (Calculate fees after entry of this Amendment.)
15. ☐ A copy of the Information Disclosure Statement from prior application. Pursuant to 37 C.F.R. 1.97(d), copies of the cited references are not enclosed.


DATE OF DEPOSIT: October 10, 2000

16. [X] I hereby verify that the attached papers are a true copy of prior application Serial No. 09/183,374, as originally filed on October 30, 1998.
17. [X] A paper copy of a Sequence Listing is included in the Application.
18. [X] A Request for Transfer of Computer Readable Form.
19. [X] I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

The undersigned declares further that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:

*October 10, 2000*



Christine E. Dietzel, Ph.D.

Agent for Applicant(s)

Registration No. 37,309

KLAUBER & JACKSON  
411 Hackensack Avenue  
Hackensack, New Jersey 07601  
(201) 487-5800

**MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC  
ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES  
THEREOF**

The research leading to the present inventions was funded in part by Grant No.  
5 DK 41096 from the National Institutes of Health. The government may have  
certain rights in the invention.

**RELATED APPLICATIONS**

The present application is a continuation-in-part of copending application Serial  
No. 08/292,345, filed August 17, 1994, of which the instant application claims the  
10 benefit of the filing date pursuant to 35 U.S.C. § 120, and which is incorporated  
herein by reference in its entirety.

**TECHNICAL FIELD OF THE INVENTION**

The present invention relates generally to the control of body weight of mammals  
including animals and humans, and more particularly to materials identified herein  
15 as modulators of weight, and to the diagnostic and therapeutic uses to which such  
modulators may be put.

**BACKGROUND OF THE INVENTION**

Obesity, defined as an excess of body fat relative to lean body mass, is associated  
with important psychological and medical morbidities, the latter including  
20 hypertension, elevated blood lipids, and Type II or non-insulin-dependent diabetes  
melitis (NIDDM). There are 6-10 million individuals with NIDDM in the U.S.,  
including 18% of the population of 65 years of age (Harris *et al.*, 1987).  
Approximately 45% of males and 70% of females with NIDDM are obese, and  
their diabetes is substantially improved or eliminated by weight reduction (Harris,  
25 1991). As described below, both obesity and NIDDM are strongly heritable,  
though the predisposing genes have not been identified. The molecular genetic

0955547-101000

basis of these metabolically related disorders is an important, poorly understood problem.

The assimilation, storage, and utilization of nutrient energy constitute a complex homeostatic system central to survival of metazoa. Among land-dwelling mammals, storage in adipose tissue of large quantities of metabolic fuel as triglycerides is crucial for surviving periods of food deprivation. The need to maintain a fixed level of energy stores without continual alterations in the size and shape of the organism requires the achievement of a balance between energy intake and expenditure. However, the molecular mechanisms that regulate energy balance remain to be elucidated. The isolation of molecules that transduce nutritional information and control energy balance will be critical to an understanding of the regulation of body weight in health and disease.

An individual's level of adiposity is, to a large extent, genetically determined. Examination of the concordance rates of body weight and adiposity amongst mono- and dizygous twins or adoptees and their biological parents have suggested that the heritability of obesity (0.4-0.8) exceeds that of many other traits commonly thought to have a substantial genetic component, such as schizophrenia, alcoholism, and atherosclerosis (Stunkard *et al.*, 1990). Familial similarities in rates of energy expenditure have also been reported (Bogardus *et al.*, 1986). Genetic analysis in geographically delimited populations has suggested that a relatively small number of genes may account for the 30%-50% of variance in body composition (Moll *et al.*, 1991). However, none of the genes responsible for obesity in the general population have been genetically mapped to a definite chromosomal location.

Rodent models of obesity include seven apparently single-gene mutations. The most intensively studied mouse obesity mutations are the *ob* (obese) and *db* (diabetes) genes. When present on the same genetic strain background, *ob* and *db* result in indistinguishable metabolic and behavioral phenotypes, suggesting that

these genes may function in the same physiologic pathway (Coleman, 1978). Mice homozygous for either mutation are hyperphagic and hypometabolic, leading to an obese phenotype that is notable at one month of age. The weight of these animals tends to stabilize at 60-70 g (compared with 30-35 g in control mice). *ob* and *db* animals manifest a myriad of other hormonal and metabolic changes that have made it difficult to identify the primary defect attributable to the mutation (Bray *et al.*, 1989).

Each of the rodent obesity models is accompanied by alterations in carbohydrate metabolism resembling those in Type II diabetes in man. In some cases, the severity of the diabetes depends in part on the background mouse strain (Leiter, 1989). For both *ob* and *db*, congenic C57BL/Ks mice develop a severe diabetes with ultimate  $\beta$  cell necrosis and islet atrophy, resulting in a relative insulinopenia. Conversely, congenic C57BL/6J *ob* and *db* mice develop a transient insulin-resistant diabetes that is eventually compensated by  $\beta$  cell hypertrophy resembling human Type II diabetes.

The phenotype of *ob* and *db* mice resembles human obesity in ways other than the development of diabetes - the mutant mice eat more and expend less energy than do lean controls (as do obese humans). This phenotype is also quite similar to that seen in animals with lesions of the ventromedial hypothalamus, which suggests that both mutations may interfere with the ability to properly integrate or respond to nutritional information within the central nervous system. Support for this hypothesis comes from the results of parabiosis experiments (Coleman, 1973) that suggest *ob* mice are deficient in a circulating satiety factor and that *db* mice are resistant to the effects of the *ob* factor (possibly due to an *ob* receptor defect). These experiments have led to the conclusion that obesity in these mutant mice may result from different defects in an afferent loop and/or integrative center of the postulated feedback mechanism that controls body composition.

Using molecular and classical genetic markers, the *ob* and *db* genes have been mapped to proximal chromosome 6 and midchromosome 4, respectively (Bahary *et al.*, 1990; Friedman *et al.*, 1991b). In both cases, the mutations map to regions of the mouse genome that are syntenic with human, suggesting that, if there are human homologs of *ob* and *db*, they are likely to map, respectively, to human chromosomes 7q and 1p. Defects in the *db* gene may result in obesity in other mammalian species: in genetic crosses between Zucker *fafa* rats and Brown Norway *+/+* rats, the *fa* mutation (rat chromosome 5) is flanked by the same loci that flank *db* in mouse (Truett *et al.*, 1991).

- 10 Because of the myriad factors that seem to impact body weight, it is difficult to speculate as to which of these factors, and more particularly, which homeostatic mechanism is actually primarily determinative. Nonetheless, the apparent connection between the *ob* gene and the extent and characteristics of obesity have prompted the further investigation and elucidation that is reflected by the present application. It is the identification of the sequence of the gene and corresponding peptide materials, to which the present invention following below directs itself.

The citation of any reference herein should not be construed as an admission that such reference is prior art to the instant invention. Full citations of references cited by author and year are found at the end of the specification.

20

### SUMMARY OF THE INVENTION

- In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleic acids or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object are believed to represent the genes corresponding to the murine and human *ob* gene, that is postulated to play a critical role in the regulation of body weight and adiposity. Data presented herein indicates that the polypeptide product of the gene

in question is secreted by the cells that express it and that the polypeptide functions as a hormone.

In a first instance, the modulators of the present invention comprise nucleic acid molecules, including recombinant DNA molecules (*e.g.*, cDNA or a vector  
5 containing the cDNA or isolated genomic DNA) or cloned genes (*i.e.* isolated genomic DNA), or degenerate variants thereof, which encode polypeptides themselves serving as modulators of weight control as hereinafter defined, or conserved variants or fragments thereof, particularly such fragments lacking the signal peptide (alternatively referred to herein as mature ob polypeptide), which  
10 polypeptides possess amino acid sequences such as set forth in FIGURE 1 (SEQ ID NO:2), FIGURE 3 (SEQ ID NO:4), FIGURE 5 (SEQ ID NO:5) and FIGURE 6 (SEQ ID NO:6). In specific embodiments, amino acid sequences for two variants of murine and human ob polypeptides are provided. Both polypeptides are found in a form with glutamine 49 deleted, which may result from an mRNA  
15 splicing anomaly. The ob polypeptides from various species may be highly homologous; as shown in Figure 4, murine and human ob polypeptides are greater than 80% homologous.

The nucleic acid molecules, recombinant DNA molecules, or cloned genes, may have the nucleotide sequences or may be complementary to DNA coding sequences  
20 shown in FIGURE 1 (SEQ ID NO:1) and FIGURE 2 (SEQ ID NO:3). In particular, such DNA molecules can be cDNA or genomic DNA isolated from the chromosome. Nucleic acid molecules of the invention may also correspond to 5' and 3' flanking sequences of the DNA. Accordingly, the present invention also relates to the identification of a gene having a nucleotide sequence selected from  
25 the sequences of Figure 1 (SEQ ID NO:1) and Figure 2 (SEQ ID NO:3) herein, and degenerate variants, allelic variations, and like cognate molecules.



A nucleic acid molecule of the invention can be DNA or RNA, including synthetic variants thereof having phosphate or phosphate analog, *e.g.*, thiophosphate, bonds. Both single stranded and double stranded sequences are contemplated herein.

The present invention further provides nucleic acid molecules for use as molecular probes, or as primers for polymerase chain reaction (PCR) amplification, *i.e.*, synthetic or natural oligonucleotides having a sequence corresponding to a portion of the sequences shown in Figure 1 (SEQ ID NO:1), Figure 2 (SEQ ID NO:3) and Figure 20A (SEQ ID NO:22), or the 5' and 3' flanking sequences of the coding sequences. In particular, the invention contemplates a nucleic acid molecule having at least about 10 nucleotides, wherein a sequence of the nucleic acid molecule corresponds to a nucleotide sequence of the same number of nucleotides in the nucleotide sequences of Figure 1 (SEQ ID NO:1), Figure 2 (SEQ ID NO:3) and Figure 20A (SEQ ID NO:22), or a sequence complementary thereto. More preferably, the nucleic acid sequence of the molecule has at least 15 nucleotides. Most preferably, the nucleic acid sequence has at least 20 nucleotides. In an embodiment of the invention in which the oligonucleotide is a probe, the oligonucleotide is detectably labeled, *e.g.*, with a radionuclide (such as <sup>32</sup>P), or an enzyme.

In further aspects, the present invention provides a cloning vector, which comprises the nucleic acids of the invention that encode the ob polypeptide; and a bacterial, insect, or a mammalian expression vector, which comprises the nucleic acid molecules of the invention encoding the ob polypeptide, operatively associated with an expression control sequence. Accordingly, the invention further relates to a host cell, such as a bacterial cell, yeast cell, insect cell, or a mammalian cell, transfected or transformed with an appropriate expression vector, and correspondingly, to the use of the above mentioned constructs in the preparation of the modulators of the invention.

In yet a further aspect, the present invention relates to antibodies that bind to the ob polypeptide. Such antibodies may be generated against the full length polypeptide, or antigenic fragments thereof. In one aspect, such antibodies inhibit the functional (*i.e.*, body weight and fat composition modulating) activity of the ob polypeptide.

All of the foregoing materials are to be considered herein as modulators of body weight and fat composition, and as such, may be used in a variety of contexts. Specifically, the invention contemplates both diagnostic and therapeutic applications, as well as certain agricultural applications, all contingent upon the use of the modulators defined herein, including both nucleic acid molecules and peptides. Moreover, the modulation of body weight carries specific therapeutic implications and benefits, in that conditions where either obesity or, conversely, cachexia represent undesired bodily conditions, can be remedied by the administration of one or more of the modulators of the present invention.

Thus, a method for modulating body weight of a mammal is proposed that comprises controlling the expression of the protein encoded by a nucleic acid having nucleotide sequence selected from the sequence of Figure 1 (SEQ ID NO:1), the sequence of Figure 2 (SEQ ID NO:3) and degenerate and allelic variants thereof. Such control may be effected by the introduction of the nucleotides in question by gene therapy into fat cells of the patient or host to control or reduce obesity. Conversely, the preparation and administration of antagonists to the nucleotides, such as anti-sense molecules, would be indicated and pursued in the instance where conditions involving excessive weight loss, such as anorexia nervosa, cancer, or AIDS are present and under treatment. Such constructs would be introduced in similar fashion to the nucleotides, directly into fat cells to effect such changes.

Correspondingly, the proteins defined by Figures 1, 3, 5, and 6 (SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6), conserved variants, active

fragments thereof, and cognate small molecules could be formulated for direct administration for therapeutic purposes, to effect reduction or control of excessive body fat or weight gain. Correspondingly, antibodies and other antagonists to the stated protein materials, such as fragments thereof, could be prepared and

5 similarly administered to achieve the converse effect. Accordingly, the invention is advantageously directed to a pharmaceutical composition comprising an ob polypeptide of the invention, or alternatively an antagonist thereof, in an admixture with a pharmaceutically acceptable carrier or excipient.

The diagnostic uses of the present nucleotides and corresponding peptides extend

10 to the use of the nucleotides to identify further mutations of allelic variations thereof, so as to develop a repertoire of active nucleotide materials useful in both diagnostic and therapeutic applications. In particular, both homozygous and heterozygous mutations of the nucleotides in question could be prepared that would be postulated to more precisely quantitate the condition of patients, to determine

15 the at-risk potential of individuals with regard to obesity. Specifically, heterozygous mutations are presently viewed as associated with mild to moderate obesity, while homozygous mutations would be associated with a more pronounced and severe obese condition. Corresponding DNA testing could then be conducted utilizing the aforementioned ascertained materials as benchmarks, to facilitate an

20 accurate long term prognosis for particular tendencies, so as to be able to prescribe changes in either dietary or other personal habits, or direct therapeutic intervention, to avert such conditions.

The diagnostic utility of the present invention extends to methods for measuring the presence and extent of the modulators of the invention in cellular samples or

25 biological extracts (or samples) taken from test subjects, so that both the encoded nucleotide (genomic DNA or RNA) and or the levels of protein in such test samples could be ascertained. Given that the increased activity of the nucleotide and presence of the resulting protein reflect the capability of the subject to inhibit obesity, the physician reviewing such results in an obese subject would determine

that a factor other than dysfunction with respect to the presence and activity of the nucleotides of the present invention is a cause of the obese condition. Conversely, depressed levels of the nucleotide and or the expressed protein would suggest that such levels must be increased to treat such obese condition, and an appropriate  
5 therapeutic regimen could then be implemented.

Further, the nucleotides discovered and presented in Figures 1 and 2 represent cDNA in which, as stated briefly above, is useful in the measurement of corresponding RNA. Likewise, recombinant protein material corresponding to the polypeptides of Figures 1 and 3 may be prepared and appropriately labeled, for  
10 use, for example, in radioimmunoassays, for example, for the purpose of measuring fat and/or plasma levels of the ob protein, or for detecting the presence and level of a receptor for ob on tissues, such as the hypothalamus.

Yet further, the present invention contemplates not only the identification of the nucleotides and corresponding proteins presented herein, but the elucidation of the  
15 receptor to such materials. In such context, the polypeptides of Figures 1, 3, 5, and/or 6 could be prepared and utilized to screen an appropriate expression library to isolate active receptors. The receptor could thereafter be cloned, and the receptor alone or in conjunction with the ligand could thereafter be utilized to screen for small molecules that may possess like activity to the modulators herein.

20 Yet further, the present invention relates to pharmaceutical compositions that include certain of the modulators hereof, preferably the polypeptides whose sequences are presented in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, their antibodies, corresponding small molecule agonists or antagonists thereof, or active fragments prepared in formulations for a variety of modes of  
25 administration, where such therapy is appropriate. Such formulations would include pharmaceutically acceptable carriers, or other adjuvants as needed, and would be prepared in effective dosage ranges to be determined by the clinician or the physician in each instance.

Accordingly, it is a principal object of the present invention to provide modulators of body weight as defined herein in purified form, that exhibit certain characteristics and activities associated with control and variation of adiposity and fat content of mammals.

- 5 It is a further object of the present invention to provide methods for the detection and measurement of the modulators of weight control as set forth herein, as a means of the effective diagnosis and monitoring of pathological conditions wherein the variation in level of such modulators is or may be a characterizing feature.

- 10 It is a still further object of the present invention to provide a method and associated assay system for the screening of substances, such as drugs, agents and the like, that are potentially effective to either mimic or inhibit the activity of the modulators of the invention in mammals.

- 15 It is a still further object of the present invention to provide a method for the treatment of mammals to control body weight and fat content in mammals, and or to treat certain of the pathological conditions of which abnormal depression or elevation of body weight is a characterizing feature.

- 20 It is a still further object of the present invention to prepare genetic constructs for use in genetic therapeutic protocols and or pharmaceutical compositions for comparable therapeutic methods, which comprise or are based upon one or more of the modulators, binding partners, or agents that may control their production, or that may mimic or antagonize their activities.

Other objects and advantages will become apparent to those skilled in the art from a review of the ensuing description which proceeds with reference to the following illustrative drawings.

### BRIEF DESCRIPTION OF THE DRAWINGS

**FIGURE 1** depicts the nucleic acid sequence (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) derived for the murine *ob* cDNA. A 97 base pair 5' leader was followed by a predicted 167 amino acid open reading frame and an approximately 3700 kb 3' untranslated sequence. A total of about 2500 base pairs of the 3' untranslated sequence is shown. Analysis of the predicted protein sequence by observation and using the *SigSeq* computer program indicates the presence of a signal sequence (underlined). Microheterogeneity of the cDNA was noted in that approximately 70% of the cDNAs had a glutamine codon at codon 49 and 30% did not (see FIGURES 5 and 6, *infra*). This amino acid is underlined, as is the arginine codon that is mutated in C57BL/6J *ob/ob* mice (1J mice).

**FIGURE 2** depicts the nucleic acid sequence (SEQ ID NO:3) derived for the human *ob* cDNA. The nucleotides are numbered from 1 to 701 with a start site at nucleotide 46 and a termination at nucleotide 550.

**FIGURE 3** depicts the full deduced amino acid sequence (SEQ ID NO:4) derived for the human *ob* gene corresponding to the nucleic acid sequence of FIGURE 2. The amino acids are numbered from 1 to 167. A signal sequence cleavage site is located after amino acid 21 (Ala) so that the mature protein extends from amino acid 22 (Val) to amino acid 167 (Cys).

**FIGURE 4** depicts the comparison between the murine (SEQ ID NO:2) and human (SEQ ID NO:4) deduced amino acid sequences. The sequence of the human *ob* deduced amino acid sequence was highly homologous to that of mouse. Conservative changes are noted by a dash, and non-conservative changes by an asterisk. The variable glutamine codon is underlined, as is the position of the nonsense mutation in C57BL/6J *ob/ob* (1J) mice. Overall, there is 84% identity at the amino acid level, although only six substitutions were found between the valine

at codon 22 (immediately downstream of the signal sequence overage) and the cysteine at position 117.

**FIGURE 5** depicts the full length amino acid sequence (SEQ ID NO:5) derived for the murine *ob* gene as shown in FIGURE 3, but lacking glutamine at position 49. The nucleotides are numbered from 1 to 166. A signal sequence cleavage site is located after amino acid 21 (Ala) (and thus, before the glutamine 49 deletion) so that the mature protein extends from amino acid 22 (Val) to amino acid 166 (Cys).

**FIGURE 6** depicts the full deduced amino acid sequence (SEQ ID NO:6) derived for the human *ob* gene as shown in FIGURE 4, but lacking glutamine at position 49. The nucleotides are numbered from 1 to 166. A signal sequence cleavage site is located after amino acid 21 (Ala) (and thus, before the glutamine 49 deletion) so that the mature protein extends from amino acid 22 (Val) to amino acid 166 (Cys).

**FIGURE 7.** (A) Physical map of the location of *ob* in the murine chromosome, and the YAC and P1 cloning maps. "M and N" corresponds to *MuI* and *NotI* restriction sites. The numbers correspond to individual animals that were recombinant in the region of *ob* of the 1606 meioses that were scored. Met, Pax 4, D6Rck39, D6Rck13, and Cpa refer to locations in the region of *ob* that bind to the DNA probes. YACs were isolated using D6Rck13 and Pax-4 as probes, and the ends were recovered using vectorette PCR and/or plasmid end rescue and used in turn to isolate new YACs. (B) The resulting YAC contig. One of the YACs in this contig, Y902A0925, was chimeric. Each of the probes used to genotype the recombinant animals is indicated in parentheses. (6) Corresponds to YAC 107; (5) corresponds to M16(+) (or M16(pLUS)); (4) corresponds to *adu*(+); (3) corresponds to *aad*(pICL); (2) corresponds to 53(pICL); and (1) corresponds to 53(+). (C) The P1 contig of bacteriophage P1 clones isolated with selected YAC end probes. The *ob* gene was isolated in a P1 clone isolated using the distal end of YAC YB6S2F12 (end (4)) (alternatively termed herein *adu*(+)).

**FIGURE 8** presents a photograph of an ethidium bromide stain of 192 independent isolates of the fourth exon trapping experiment that were PCR amplified and characterized.

**FIGURE 9** is a photograph of an ethidium bromide stain of PCR-amplified clones suspected of carrying *ob*. Each of the 7 clones that did not carry the artifact was reamplified using PCR and electrophoresed on a 1% agarose gel in TBE and stained with ethidium bromide. The size markers (far left unnumbered lane) are the commercially available "1 kB ladder". Lane 1 -- clone 1D12, containing an "HIV sequence." Lane 2 -- clone 1F1, a novel clone outside of the *ob* region.

5      Lane 3 -- clone 1H3. Lane 4 -- clone 2B2, which is identical to 1F1. Lane 10      5 -- clone 2G7, which contains an *ob* exon. Lane 6 -- clone 2G11, which is identical to 1F1. Lane 7 -- clone 2H1, which does not contain an insert.

**FIGURE 10** presents the sequence of the 2G7 clone (SEQ ID NO:7), which includes an exon coding for a part of the *ob* gene. The primer sequences used to

15      amplify this exon are boxed in the figure (SEQ ID NOS:8 and 9).

**FIGURE 11.** (A) Reverse transcription-PCR analysis of mRNA from different tissues of the same mouse with the 2G7 primers and actin primers. The RT-PCR reactions were performed using 100 ng of total RNA reverse transcribed with oligo dT as a primer for first strand cDNA. PCR amplification was performed for

20      35 cycles with 94° denaturation x 1'; 55° hybridization x 1'; and 72 extensions for 2' with a 1' second autoextension per cycle. RT-PCR products were resolved in a 2% low melting point agarose gel run in 1x TBE buffer. (B) Northern blot of mRNA from different organs of the mouse using PCR labeled 2G7 as a probe. Ten µg of total RNA from each of the tissues was electrophoresed on an agarose

25      gel with formaldehyde. The probe was hybridized at 65°C in Rapid Hybe (Amersham). Autoradiographic signals were apparent after 1 hour of exposure; the experiment shown was the result of a 24 hour exposure.



**FIGURE 12.** (A) An ethidium bromide stain from an RT PCR reaction on fat cell (white adipose tissue) RNA from each of the mouse strains listed. Total RNA (100 ng) for each sample was reverse transcribed using oligo dT and reverse transcriptase, and the resulting single stranded cDNA was PCR amplified with the 2G7 primers (lower bands) or actin primers (upper bands). Both the 2G7 and actin primers were included in the same PCR reaction. The products were run on a 1% agarose TBE gel. (B) Northern analysis corresponding to (A). Ten  $\mu$ g of fat cell (white adipose tissue) RNA from each of the strains indicated were run out and probed with the PCR labeled 2G7 probe as in Figure 11B, above. An approximately 20-fold increase in the level of 2G7 mRNA was apparent in white fat RNA from the C57BL/6J ob/ob (1J) strain relative to lean littermates. In both the RT-PCR and Northern experiments there was no detectable signal in 2G7 RNA from the SM/Ckc-+<sup>Dac</sup>ob<sup>2J</sup>/ob<sup>2J</sup> (2J) mice even after a 2 week exposure. A 24 hour autoradiographic exposure is shown. The same filter was hybridized to an actin probe (bottom portion of the panel).

**FIGURE 13** is a Northern analysis of additional 2J animals and control animals that confirms the absence of the *ob* mRNA from 2J animals. The Northern analysis was performed as in Figures 11 and 12. In this case, the control RNA was ap2, a fat specific transcript. There is no significance to the varying density of the ap2 bands.

**FIGURE 14** compares the DNA sequence of the C57BL/6J (normal) and the C57BL/6J ob/ob (1J) mice in the region of the point mutation that leads to introduction of a premature stop codon (nonsense mutation) in the mutant strain cDNA. The ob/ob mice had a C→T mutation that changed an arginine residue at position 105. This base change is shown as the output from the automated DNA sequencer. RT-PCR was performed using white fat RNA from both strains (+/+ and ob/ob) using primers from the 5' and 3' untranslated regions. The PCR reaction products were gel purified and directly sequenced manually and using an

ABI 373A automated sequencer with primers along both strands of the coding sequence.

**FIGURE 15.** (A) Genomic southern blot of genomic DNA from each of the mouse strains listed. Approximately 5  $\mu$ g of DNA (derived from genomic DNA prepared from liver, kidney or spleen) was restriction digested with the restriction enzyme indicated. The DNA was then electrophoresed in a 1% agarose TBE gel and probed with PCR labeled 2G7. Restriction digestion with *Bgl*III revealed an increase in the size of an approximately 9 kB (the largest) *Bgl*III fragment in SM/Ckc-+Dacob<sup>2J</sup>/ob<sup>2J</sup> (2J) DNA. RFLPs were not detectable with any other restriction enzymes. Preliminary restriction mapping of genomic DNA indicated that the polymorphic *Bgl*III site is about 7 kB upstream of the transcription start site. None of the other enzymes tested extend past the mRNA start site. (B) Segregation of a *Bgl*III polymorphism in the SM/Ckc-+Dacob<sup>2J</sup>/ob<sup>2J</sup> strain. Six obese and five lean progeny from the same generation of the coisogenic SM/Ckc-+<sup>Dac</sup>ob<sup>2J</sup>/ob<sup>2J</sup> (2J) colony were genotyped by scoring the *Bgl*III polymorphism as shown in (A). All of the phenotypically obese animals were homozygous for the larger allele of the polymorphic *Bgl* fragment. The DNA in the "control" lane was prepared from an unrelated SM/Ckc-+<sup>Dac</sup>+/+ mouse, bred separately from the SM/Ckc-+<sup>Dac</sup>ob<sup>2J</sup>/ob<sup>2J</sup> colony.

**FIGURE 16** is a Southern blot of EcoRI digested genomic DNA from the species listed, using an *ob* cDNA as a probe (*i.e.*, a zoo blot). Hybridization signals were detectable in every vertebrate sample, even after a moderate stringency hybridization. The cat DNA in this experiment was slightly degraded. The restricted DNA was run on a 1% agarose TBE gel, and transferred to an imobilon membrane for probing. The filter was hybridized at 65°C and washed in 2X SSC/0.2% SDS at 65°C twice for twenty minutes and exposed for 3 days using Kodak X-OMAT film.

**FIGURE 17** presents the expression cloning region of vector pET-15b (Novagen).

**FIGURE 18** presents analysis of the eluate from a His-binding resin (Ni) column for a recombinant mature murine ob fusion to a His-tag (A) and mature human ob fusion to a His-tag (B). Bacteria transformed with vectors pETM9 and pETH14, respectively. Upon induction with 1 mM IPTG at optimal conditions, the

5 transformed bacteria were able to produce 100-300  $\mu\text{g/ml}$  of ob fusion protein, primarily in the inclusion body. The inclusion body was solubilized with 6M guanidine-HCl or urea, and fusion protein (present in the lysis supernatant) was loaded on the His-binding resin (Ni) column in 10 ml of 1x binding buffer with urea. The column was eluted stepwise with 5 ml aliquots of 20  $\mu\text{M}$ , 60  $\mu\text{M}$ , and

10 300  $\mu\text{M}$  imidazole, and finally with strip buffer. The aliquots were analyzed for the presence of ob polypeptide fusion on a 15% acrylamide gel. Each lane contains the equivalent of 100  $\mu\text{l}$  of bacterial extract.

**FIGURE 19.** (A) *In vitro* translation of ob RNA. A human ob cDNA was subcloned into the pGEM vector. The plasmid was linearized and plus strand

15 RNA was synthesized using sp6 polymerase. The *in vitro* synthesized RNA was translated in the presence or absence of canine pancreatic microsomal membranes. An approximately 18 kD primary translation product was seen after *in vitro* translation. The addition of microsomal membranes to the reaction led to the appearance of a second translation product about 2 kD smaller than the primary

20 translation product. The size of the translation product of interleukin-1 $\alpha$  RNA, which lacks an encoded signal sequence, was unchanged by the addition of microsomal membranes. These data indicated the presence of a functional signal sequence. (B) *In vitro* translation in the presence or absence of proteinase K. Protease treatment resulted in complete proteolysis of the 18 kD primary

25 translation product, while the 16 kD processed form was unaffected. Permeabilization of the microsome with 0.1% TRITON-X100 rendered the processed form protease sensitive. These results indicate that the product had translated into the lumen of the microsome.

**FIGURE 20.** (A) The sequence of the human *ob* gene (SEQ ID NO:22). (B) A schematic diagram of the murine *ob* gene. (C) A schematic diagram of the human *ob* gene. In both (B) and (C), the start and stop codons are underlined. There is no evidence of a first intron homologous to the mouse first intron in the human

5 gene, but its existence cannot be excluded.

**FIGURE 21** presents a schematic drawing of one of the cloning strategies employed to achieve recombinant expression of *ob* in pichia yeast. (A) Expression vector of *ob* with an  $\alpha$ -mating factor signal sequence. (B) Schematic drawing of the structure of the recombinant fusion protein, including the amino acid sequence

10 (SEQ ID NO:23) showing the *XhoI* site and putative KEX-2 and STE-13 cleavage sites, and the N-terminal surplus amino acids present after KEX-2 cleavage (SEQ ID NO:24). (C) An alternative strategy for producing mature *ob* under involves preparing a construct with an amino acid sequence corresponding to a *XhoI* cleavage site and a KEX-2 cleavage site immediately upstream of the mature *ob*

15 polypeptide sequence (SEQ ID NO:25).

**FIGURE 22** Alternative expression strategy in pichia. (A) Expression vector of an *ob* fusion with a His tag adopted from the pET expression system under control of the  $\alpha$ -mating factor signal sequence. (B) Schematic drawing of the structure of the recombinant *ob* fusion protein containing a His tag, which includes the  $\alpha$ -

20 mating factor signal sequence, putative KEX-2 and STE-13 cleavage sites, the His-tag, and a thrombin cleavage site, and which would yield *ob* with three surplus N-terminal amino acid residues.

**FIGURE 23.** (A) PAGE analysis of expression of murine *ob* (both the microheterogenous forms, *i.e.*, containing and missing Gln 49) in transformed

25 pichia yeast. The expected band of approximately 16 kD is visible in the transformed yeast culture fluid (second and third lanes), but not in culture fluid from non-transformed yeast (first lane). (B) PAGE analysis of partially purified recombinant *ob* polypeptide on carboxymethyl cellulose, a weak cation exchanger.

A band of about 16 kD is very visible in fractions 3 and 4 from the column, which was eluted with 250 mM NaCl. Lane 1 -- loaded sample; lane 2 -- flow through; lanes 3-5 -- fractions eluted with 250 mM NaCl.

#### DETAILED DESCRIPTION

- 5 In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, *e.g.*, Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* [B.D. Hames & S.J. Higgins eds. (1985)]; *Transcription And Translation* [B.D. Hames & S.J. Higgins, eds. (1984)]; *Animal Cell Culture* [R.I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRL Press, (1986)]; B. Perbal, *A Practical Guide To Molecular Cloning* (1984). Of particular relevance to the present invention are strategies for isolating, cloning, sequencing, analyzing, and characterizing a gene or nucleic acid based on the well known polymerase chain reaction (PCR) techniques.

Therefore, if appearing herein, the following terms shall have the definitions set out below.

The term "body weight modulator", "modulator", "modulators", and any variants not specifically listed, may be used herein interchangeably, and as used throughout the present application and claims refers in one instance to both nucleotides and to proteinaceous material, the latter including both single or multiple proteins. More specifically, the aforementioned terms extend to the nucleotides and to the DNA having the sequences described herein and presented in Figure 1 (SEQ ID NO:1), and Figure 2 (SEQ ID NO:3). Likewise, the proteins having the amino acid

5 contemplated, including substantially homologous analogs and allelic variations. Likewise, proteins displaying substantially equivalent or altered activity, including proteins modified deliberately, as for example, by site-directed mutagenesis, or accidentally through mutations in hosts that produce the modulators are likewise contemplated.

15 A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*, *i.e.*, capable of replication under its own control.

A "cassette" refers to a segment of DNA that can be inserted into a vector at specific restriction sites. The segment of DNA encodes a polypeptide of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.

"Heterologous" DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell.

5 A cell has been "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. A cell has been "transformed" by exogenous or heterologous DNA when the transfected DNA effects a phenotypic change. Preferably, the transforming DNA should be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.

10 A "clone" is a population of cells derived from a single cell or common ancestor by mitosis.

15 A "nucleic acid molecule" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules") in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary or quaternary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear or circular DNA  
20 molecules (*e.g.*, restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (*i.e.*, the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule"  
25 is a DNA molecule that has undergone a molecular biological manipulation.

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic

acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (*see* Sambrook et al., *supra*). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low

5 stringency hybridization conditions, corresponding to a  $T_m$  of  $55^\circ$ , can be used, *e.g.*, 5x SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30% formamide, 5x SSC, 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher  $T_m$ , *e.g.*, 40% formamide, with 5x or 6x SCC. High stringency hybridization conditions correspond to the highest  $T_m$ , *e.g.*, 50% formamide, 5x or

10 6x SCC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of

15 similarity or homology between two nucleotide sequences, the greater the value of  $T_m$  for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher  $T_m$ ) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating  $T_m$  have been derived (*see*

20 Sambrook et al., *supra*, 9.50-0.51). For hybridization with shorter nucleic acids, *i.e.*, oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (*see* Sambrook et al., *supra*, 11.7-11.8). Preferably a minimum length for a hybridizable nucleic acid is at least about 10 nucleotides; more preferably at least about 15 nucleotides; most

25 preferably the length is at least about 20 nucleotides.

"Homologous recombination" refers to the insertion of a foreign DNA sequence of a vector in a chromosome. Preferably, the vector targets a specific chromosomal site for homologous recombination. For specific homologous recombination, the vector will contain sufficiently long regions of homology to sequences of the

30 chromosome to allow complementary binding and incorporation of the vector into



the chromosome. Longer regions of homology, and greater degrees of sequence similarity, may increase the efficiency of homologous recombination.

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (*e.g.*, mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.

A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced and translated into the protein encoded by the coding sequence.

A "signal sequence" is included at the beginning of the coding sequence of a protein to be expressed on the surface of a cell. This sequence encodes a signal peptide, N-terminal to the mature polypeptide, that directs the host cell to translocate the polypeptide. The term "translocation signal sequence" is also used herein to refer to this sort of signal sequence. Translocation signal sequences can be found associated with a variety of proteins native to eukaryotes and prokaryotes, and are often functional in both types of organisms.

A DNA sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence. The term "operatively linked" includes having an appropriate start signal (*e.g.*, ATG) in front of the DNA sequence to be

5 expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted upstream (5') of and in

10 reading frame with the gene.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and

15 extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA

20 polymerase.

The term "standard hybridization conditions" refers to salt and temperature conditions substantially equivalent to 5 x SSC and 65°C for both hybridization and wash.

A molecule is "antigenic" when it is capable of specifically interacting with an

25 antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor. An antigenic polypeptide contains at least about 5, and preferably at least about 10, amino acids. An antigenic portion of a molecule can be that portion that is immunodominant for antibody or T cell

receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier molecule for immunization. A molecule that is antigenic need not be itself immunogenic, *i.e.*, capable of eliciting an immune response without a carrier.

- 5 An "antibody" is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope. The term encompasses polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,816,397 and 4,816,567, as well as antigen binding portions of antibodies, including Fab, F(ab')<sub>2</sub> and Fr (including single chain antibodies). Accordingly,
- 10 the phrase "antibody molecule" in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule containing the antibody combining site. An "antibody combining site" is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions
- 15 that specifically binds antigen.

Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contains the paratope, including those portions known in the art as Fab, Fab', F(ab')<sub>2</sub> and F(v), which portions are preferred for use in the

20 therapeutic methods described herein.

Fab and F(ab')<sub>2</sub> portions of antibody molecules are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibody molecules by methods that are well-known. See for example, U.S. Patent No. 4,342,566 to Theofilopolous et al. Fab' antibody molecule portions are also well-

25 known and are produced from F(ab')<sub>2</sub> portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as

iodoacetamide. An antibody containing intact antibody molecules is preferred herein.

The phrase "monoclonal antibody" in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of

- 5 immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different antigen; e.g., a bispecific (chimeric) monoclonal antibody.
- 10 A composition comprising "A" (where "A" is a single protein, DNA molecule, vector, recombinant host cell, etc.) is substantially free of "B" (where "B" comprises one or more contaminating proteins, DNA molecules, vectors, etc., but excluding racemic forms of A) when at least about 75% by weight of the proteins, DNA, vectors (depending on the category of species to which A and B belong) in
- 15 the composition is "A". Preferably, "A" comprises at least about 90% by weight of the A+B species in the composition, most preferably at least about 99% by weight. It is also preferred that a composition, which is substantially free of contamination, contain only a single molecular weight species having the activity or characteristic of the species of interest.
- 20 The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the
- 25 Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be

5 injectable solutions. Suitable pharmaceutical carriers are described in  
"Remington's Pharmaceutical Sciences" by E.W. Martin.

10 significant deficit in the activity, function and response of the host. Alternatively,  
a therapeutically effective amount is sufficient to cause an improvement in a  
clinically significant condition in the host.

releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood et al., *Immunology, Second Ed.*, 1984, Benjamin/Cummings: Menlo Park, California, p. 384). Often, a primary challenge with an antigen alone, in the absence of an adjuvant, will fail to elicit a humoral or cellular immune response. Adjuvants include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*. Preferably, the adjuvant is pharmaceutically acceptable.

In its primary aspect, the present invention is directed to the identification of materials that function as modulators of mammalian body weight. In particular, the invention concerns the isolation, purification and sequencing of certain nucleic

acids that correspond to the *ob* gene in both mice and humans, as well as the corresponding polypeptides expressed by these nucleic acids. The invention thus comprises the discovery of nucleic acids having the nucleotide sequences set forth in FIGURE 1 (SEQ ID NO:1) and FIGURE 2 (SEQ ID NO:3), and to degenerate  
5 variants, alleles and fragments thereof, all possessing the activity of modulating body weight and adiposity. The correspondence of the present nucleic acids to the *ob* gene portends their significant impact on conditions such as obesity as well as other maladies and dysfunctions where abnormalities in body weight are a contributory factor. The invention extends to the proteins expressed by the nucleic  
10 acids of the invention, and particularly to those proteins set forth in FIGURE 1 (SEQ ID NO:2), FIGURE 3 (SEQ ID NO:4), FIGURE 5 (SEQ ID NO:5), and FIGURE 6 (SEQ ID NO:6), as well as conserved variants, active fragments, and cognate small molecules.

In particular, the present invention contemplates that naturally occurring fragments  
15 of the *ob* polypeptide may be important. The peptide sequence includes a number of sites that are frequently the target for proteolytic cleavage, *e.g.*, arginine residues. It is possible that the full length polypeptide may be cleaved at one or more such sites to form biologically active fragments. Such biologically active fragments may either agonize or antagonize the functional activity of the *ob*  
20 polypeptide to reduce body weight.

As discussed earlier, the weight control modulator peptides or their binding partners or other ligands or agents exhibiting either mimicry or antagonism to them or control over their production, may be prepared in pharmaceutical compositions, with a suitable carrier and at a strength effective for administration  
25 by various means to a patient experiencing abnormal fluctuations in body weight or adiposity, either alone or as part of an adverse medical condition such as cancer or AIDS, for the treatment thereof. A variety of administrative techniques may be utilized, among them parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, catheterizations and the like. Average quantities of the

recognition factors or their subunits may vary and in particular should be based upon the recommendations and prescription of a qualified physician or veterinarian.

Also, antibodies including both polyclonal and monoclonal antibodies, and drugs  
 5 that modulate the production or activity of the weight control modulators  
 recognition factors and/or their subunits may possess certain diagnostic  
 applications and may for example, be utilized for the purpose of detecting and/or  
 measuring conditions where abnormalities in body weight are or may be likely to  
 develop. For example, the modulator peptides or their active fragments may be  
 10 used to produce both polyclonal and monoclonal antibodies to themselves in a  
 variety of cellular media, by known techniques such as the hybridoma technique  
 utilizing, for example, fused mouse spleen lymphocytes and myeloma cells. These  
 techniques are described in detail below. Likewise, small molecules that mimic or  
 antagonize the activity(ies) of the receptor recognition factors of the invention may  
 15 be discovered or synthesized, and may be used in diagnostic and/or therapeutic  
 protocols.

Panels of monoclonal antibodies produced against modulator peptides can be  
 screened for various properties; i.e., isotype, epitope, affinity, etc. Of particular  
 interest are monoclonal antibodies that neutralize the activity of the modulator  
 20 peptides. Such monoclonals can be readily identified in activity assays for the  
 weight modulators. High affinity antibodies are also useful when immunoaffinity  
 purification of native or recombinant modulator is possible.

Preferably, the anti-modulator antibody used in the diagnostic and therapeutic  
 methods of this invention is an affinity purified polyclonal antibody. More  
 25 preferably, the antibody is a monoclonal antibody (mAb). In addition, it is  
 preferable for the anti-modulator antibody molecules used herein be in the form of  
 Fab, Fab', F(ab')<sub>2</sub> or F(v) portions of whole antibody molecules.

As suggested earlier, a diagnostic method useful in the present invention comprises examining a cellular sample or medium by means of an assay including an effective amount of an antagonist to a modulator protein, such as an anti-modulator antibody, preferably an affinity-purified polyclonal antibody, and more preferably a mAb. In addition, it is preferable for the anti-modulator antibody molecules used herein be in the form of Fab, Fab', F(ab')<sub>2</sub> or F(v) portions or whole antibody molecules. As previously discussed, patients capable of benefiting from this method include those suffering from cancer, AIDS, obesity or other condition where abnormal body weight is a characteristic or factor. Methods for isolating the modulator and inducing anti-modulator antibodies and for determining and optimizing the ability of anti-modulator antibodies to assist in the examination of the target cells are all well-known in the art.

The nucleic acids contemplated by the present invention extend as indicated, to other nucleic acids that code on expression for peptides such as those set forth in FIGURE 1 (SEQ ID NO:2), FIGURE 3 (SEQ ID NO:4), FIGURE 5 (SEQ ID NO:5), and FIGURE 6 (SEQ ID NO:6) herein. Accordingly, while specific DNA has been isolated and sequenced in relation to the *ob* gene, any animal cell potentially can serve as the nucleic acid source for the molecular cloning of a gene encoding the peptides of the invention. The DNA may be obtained by standard procedures known in the art from cloned DNA (*e.g.*, a DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (See, for example, Sambrook et al., 1989, *supra*; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II). Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will not contain intron sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.



- In the molecular cloning of the gene from genomic DNA, the genomic DNA can be amplified using primers selected from the cDNA sequences. Alternatively, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. One may
- 5 also use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.
- 10 Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired *ob* or *ob*-like gene may be accomplished in a number of ways. For example, if an amount of a portion of a *ob* or *ob*-like gene or its specific RNA, or a fragment thereof, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid
- 15 hybridization to the labeled probe (Benton and Davis, 1977, *Science* 196:180; Grunstein and Hogness, 1975, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961). The present invention provides such nucleic acid probes, which can be conveniently prepared from the specific sequences disclosed herein, *e.g.*, a hybridizable probe having a nucleotide sequence corresponding to at least a 10, and preferably a 15,
- 20 nucleotide fragment of the sequences depicted in Figure 1 (SEQ ID NO:1) or Figure 2 (SEQ ID NO:3). Preferably, a fragment is selected that is highly unique to the modulator peptides of the invention. Those DNA fragments with substantial homology to the probe will hybridize. As noted above, the greater the degree of homology, the more stringent hybridization conditions can be used. In one
- 25 embodiment, low stringency hybridization conditions are used to identify a homologous modulator peptide. However, in a preferred aspect, and as demonstrated experimentally herein, a nucleic acid encoding a modulator peptide of the invention will hybridize to a nucleic acid having a nucleotide sequence such as depicted in Figure 1 (SEQ ID NO:1) or Figure 2 (SEQ ID NO:3), or a

hybridizable fragment thereof, under moderately stringent conditions; more preferably, it will hybridize under high stringency conditions.

Alternatively, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, *e.g.*, has similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, tyrosine phosphatase activity or antigenic properties as known for the present modulator peptides. For example, the antibodies of the instant invention can conveniently be used to screen for homologs of modulator peptides from other sources.

A gene encoding a modulator peptide of the invention can also be identified by mRNA selection, *i.e.*, by nucleic acid hybridization followed by *in vitro* translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified modulator DNA. Immunoprecipitation analysis or functional assays (*e.g.*, tyrosine phosphatase activity) of the *in vitro* translation products of the products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments, that contain the desired sequences. In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against a modulator peptide.

A radiolabeled modulator peptide cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabeled mRNA or cDNA may then be used as a probe to identify homologous modulator peptide DNA fragments from among other genomic DNA fragments.

Another feature of this invention is the expression of the DNA sequences disclosed herein. As is well known in the art, DNA sequences may be expressed by

operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host.

Such operative linking of a DNA sequence of this invention to an expression control sequence, of course, includes, if not already part of the DNA sequence, the provision of an initiation codon, ATG, in the correct reading frame upstream of the DNA sequence.

A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and Synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., *E. coli* plasmids col El, pCR1, pBR322, pMB9, pUC or pUC plasmid derivatives, e.g., pGEX vectors, pET vectors, pmal-c, pFLAG, etc., and their derivatives, plasmids such as RP4; phage DNAs, e.g., the numerous derivatives of phage  $\lambda$ , e.g., NM989, and other phage DNA, e.g., M13 and Filamentous single stranded phage DNA; yeast plasmids such as the 2 $\mu$  plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like. In a preferred embodiment, expression of *ob* is achieved in methylotrophic yeast, e.g., *Pichia pastoris* yeast (see, e.g., International Patent Publication No. WO 90/03431, published 5 April 1990, by Brierley et al.; International Patent Publication No. WO 90/10697, published 20 September 1990, by Siegel et al.). In a specific embodiment, *infra*, an expression vector is engineered for expression of *ob* under control of the  $\alpha$ -mating factor signal sequence.

Any of a wide variety of expression control sequences -- sequences that control the expression of a DNA sequence operatively linked to it -- may be used in these

vectors to express the DNA sequences of this invention. Such useful expression control sequences include, for example, the early or late promoters of SV40, CMV, vaccinia, polyoma or adenovirus, the *lac* system, the *trp* system, the *TAC* system, the *TRC* system, the *LTR* system, the major operator and promoter regions of phage  $\lambda$ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase (e.g., Pho5), the AOX 1 promoter of methylotrophic yeast, the promoters of the yeast  $\alpha$ -mating factors, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.

A wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*; fungi such as yeasts (*Saccharomyces*, and methylotrophic yeast such as *Pichia*, *Candida*, *Hansenula*, and *Torulopsis*); and animal cells, such as CHO, R1.1, B-W and L-M cells, African Green Monkey kidney cells (e.g., COS 1, COS 7, BSC1, BSC40, and BMT10), insect cells (e.g., Sf9), and human cells and plant cells in tissue culture.

It will be understood that not all vectors, expression control sequences and hosts will function equally well to express the DNA sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one skilled in the art will be able to select the proper vectors, expression control sequences, and hosts without undue experimentation to accomplish the desired expression without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must function in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the vector, such as antibiotic markers, will also be considered.

In selecting an expression control sequence, a variety of factors will normally be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence or gene to be expressed, particularly as regards potential secondary structures. Suitable

- 5 unicellular hosts will be selected by consideration of, e.g., their compatibility with the chosen vector, their secretion characteristics, their ability to fold proteins correctly, and their fermentation requirements, as well as the toxicity to the host of the product encoded by the DNA sequences to be expressed, and the ease of purification of the expression products.

- 10 Considering these and other factors a person skilled in the art will be able to construct a variety of vector/expression control sequence/host combinations that will express the DNA sequences of this invention on fermentation or in large scale animal culture.

- In a specific embodiment, an ob fusion protein can be expressed. An ob fusion  
 15 protein comprises at least a functionally active portion of a non-ob protein joined via a peptide bond to at least a functionally active portion of an ob polypeptide. The non-ob sequences can be amino- or carboxy-terminal to the ob sequences. More preferably, for stable expression of a proteolytically inactive ob fusion protein, the portion of the non-ob fusion protein is joined via a peptide bond to the  
 20 amino terminus of the ob protein. A recombinant DNA molecule encoding such a fusion protein comprises a sequence encoding at least a functionally active portion of a non-ob protein joined in-frame to the ob coding sequence, and preferably encodes a cleavage site for a specific protease, e.g., thrombin or Factor Xa, preferably at the ob-non-ob juncture. In a specific embodiment, the fusion protein  
 25 is expressed in *Escherichia coli* or in *P. pastoris*.

In a specific embodiment, *infra*, vectors were prepared to express the murine and human *ob* genes, with and without the codon for gln-49, in bacterial expression systems and yeast (*Pichia*) expression systems as fusion proteins. The *ob* gene is

prepared with an endonuclease cleavage site, *e.g.*, using PCR and novel primers. It is desirable to confirm sequences generated by PCR, since the probability of including a point mutation is greater with this technique. A plasmid containing a histidine tag (HIS-TAG) and a proteolytic cleavage site is used. The presence of the histidine makes possible the selective isolation of recombinant proteins on a Ni-chelation column, or by affinity purification. The proteolytic cleavage site, in a specific embodiment, *infra*, a thrombin cleavage site, is engineered so that treatment with the protease, *e.g.*, thrombin, will release the full length mature (*i.e.*, lacking a signal sequence) ob polypeptide.

- 10 In another aspect, the pGEX vector (Smith and Johnson, 1988, Gene 67:31-40) can be used. This vector fuses the schistosoma japonicum glutathione S-transferase cDNA to the sequence of interest. Bacterial proteins are harvested and recombinant proteins can be quickly purified on a reduced glutathione affinity column. The GST carrier can subsequently be cleaved from fusion proteins by digestion with site-specific proteases. After cleavage, the carrier and uncleaved fusion protein can be removed by absorption on glutathione agarose. Difficulty with the system occasionally arises when the encoded protein is insoluble in aqueous solutions.

- 20 Expression of recombinant proteins in bacterial systems may result in incorrect folding of the expressed protein, requiring refolding. The recombinant protein can be refolded prior to or after cleavage to form a functionally active ob polypeptide. The ob polypeptide may be refolded by the steps of (i) incubating the protein in a denaturing buffer that contains a reducing agent, and then (ii) incubating the protein in a buffer that contains an oxidizing agent, and preferably also contains a protein stabilizing agent or a chaotropic agent, or both. Suitable redox (reducing/oxidizing) agent pairs include, but are not limited to, reduced glutathione/glutathione disulfide, cystine/cysteine, cystamine/cysteamine, and 2-mercaptoethanol/2-hydroxyethyl disulfide. In a particular aspect, the fusion protein can be solubilized in a denaturant, such as urea, prior to exchange into the

reducing buffer. In preferred embodiment, the protein is also purified, *e.g.*, by ion exchange or Ni-chelation chromatography, prior to exchange into the reducing buffer. Denaturing agents include but are not limited to urea and guanidine-HCl. The recombinant protein is then diluted about at least 10-fold, more preferably about 100-fold, into an oxidizing buffer that contains an oxidizing agent, such as but not limited to 0.1 M Tris-HCl, pH 8.0, 1 mM EDTA, 0.15 M NaCl, 0.3 M oxidized glutathione. The fusion protein is then incubated for about 1 to about 24 hours, preferably about 2 to about 16 hours, at room temperature in the oxidizing buffer. The oxidizing buffer may comprise a protein stabilizing agent, *e.g.*, a sugar, an alcohol, or ammonium sulfate. The oxidizing buffer may further comprises a chaotropic agent at low concentration, to destabilize incorrect intermolecular interactions and thus promote proper folding. Suitable chaotropic agents include but are not limited to a detergent, a polyol, L-arginine, guanidine-HCl and polyethylene glycol (PEG). It is important to use a low enough concentration of the chaotropic agent to avoid denaturing the protein. The refolded protein can be concentrated by at least about 10-fold, more preferably by the amount it was diluted into the oxidizing buffer.

Bacterial fermentation processes can also result in a recombinant protein preparation that contains unacceptable levels of endotoxins. Therefore, the invention contemplates removal of such endotoxins, *e.g.*, by using endotoxin-specific antibodies or other endotoxin binding molecules. The presence of endotoxins can be determined by standard techniques, such as by employing E-TOXATE Reagents (Sigma), or with bioassays.

In addition to the specific example, the present inventors contemplate use of baculovirus, mammalian, and yeast expression systems to express the ob protein. For example, in baculovirus expression systems, both non-fusion transfer vectors, such as but not limited to pVL941 (BamH1 cloning site; Summers), pVL1393 (BamH1, SmaI, XbaI, EcoRI, NotI, XmaIII, BglII, and PstI cloning site; Invitrogen), pVL1392 (BglII, PstI, NotI, XmaIII, EcoRI, XbaI, SmaI, and BamH1

cloning site; Summers and Invitrogen), and pBlueBacIII (BamHI, BglII, PstI, NcoI, and HindIII cloning site, with blue/white recombinant screening possible; Invitrogen), and fusion transfer vectors, such as but not limited to pAc700 (BamHI and KpnI cloning site, in which the BamHI recognition site begins with the initiation codon; Summers), pAc701 and pAc702 (same as pAc700, with different reading frames), pAc360 (BamHI cloning site 36 base pairs downstream of a polyhedrin initiation codon; Invitrogen(195)), and pBlueBacHisA, B, C (three different reading frames, with BamHI, BglII, PstI, NcoI, and HindIII cloning site, an N-terminal peptide for ProBond purification, and blue/white recombinant screening of plaques; Invitrogen (220)).

Mammalian expression vectors contemplated for use in the invention include vectors with inducible promoters, such as dihydrofolate reductase (DHFR), *e.g.*, any expression vector with a DHFR expression vector, or a DHFR/methotrexate co-amplification vector, such as pED (PstI, SalI, SbaI, SmaI, and EcoRI cloning site, with the vector expressing both the cloned gene and DHFR; *see* Kaufman, *Current Protocols in Molecular Biology*, 16.12, 1991). Alternatively, a glutamine synthetase/methionine sulfoximine co-amplification vector, such as pEE14 (HindIII, XbaI, SmaI, SmaI, EcoRI, and BclI cloning site, in which the vector expresses glutamine synthase and the cloned gene; Celltech). In another embodiment, a vector that directs episomal expression under control of Epstein Barr Virus (EBV) can be used, such as pREP4 (BamHI, SfiI, XhoI, NotI, NheI, HindIII, NheI, PvuII, and KpnI cloning site, constitutive RSV LTR promoter, hygromycin selectable marker; Invitrogen), pCEP4 (BamHI, SfiI, XhoI, NotI, NheI, HindIII, NheI, PvuII, and KpnI cloning site, constitutive hCMV immediate early gene, hygromycin selectable marker; Invitrogen), pMEP4 (KpnI, PvuI, NheI, HindIII, NotI, XhoI, SfiI, BamHI cloning site, inducible methallothionein IIa gene promoter, hygromycin selectable marker: Invitrogen), pREP8 (BamHI, XhoI, NotI, HindIII, NheI, and KpnI cloning site, RSV LTR promoter, histidinol selectable marker; Invitrogen), pREP9 (KpnI, NheI, HindIII, NotI, XhoI, SfiI, and BamHI cloning site, RSV LTR promoter, G418 selectable marker; Invitrogen),



and pEBVHis (RSV LTR promoter, hygromycin selectable marker, N-terminal peptide purifiable via ProBond resin and cleaved by enterokinase; Invitrogen).

Selectable mammalian expression vectors for use in the invention include

pRc/CMV (HindIII, BstXI, NotI, SbaI, and ApaI cloning site, G418 selection;

- 5 Invitrogen), pRc/RSV (HindIII, SpeI, BstXI, NotI, XbaI cloning site, G418 selection; Invitrogen), and others. Vaccinia virus mammalian expression vectors (*see*, Kaufman, *supra*) for use according to the invention include but are not limited to pSC11 (SmaI cloning site, TK- and  $\beta$ -gal selection), pMJ601 (SalI, SmaI, AflII, NarI, BspMII, BamHI, ApaI, NheI, SacII, KpnI, and HindIII cloning
- 10 site; TK- and  $\beta$ -gal selection), and pTKgptF1S (EcoRI, PstI, SalI, AccI, HindII, SbaI, BamHI, and HpaI cloning site, TK or XPRT selection).

Yeast expression systems can also be used according to the invention to express ob polypeptide. For example, the non-fusion pYES2 vector (XbaI, SphI, ShoI, NotI, GstXI, EcoRI, BstXI, BamHI, SacI, KpnI, and HindIII cloning sit; Invitrogen) or

- 15 the fusion pYESHisA, B, C (XbaI, SphI, ShoI, NotI, BstXI, EcoRI, BamHI, SacI, KpnI, and HindIII cloning site, N-terminal peptide purified with ProBond resin and cleaved with enterokinase; Invitrogen), to mention just two, can be employed according to the invention.

- 20 It is further intended that body weight modulator peptide analogs may be prepared from nucleotide sequences derived within the scope of the present invention. Analogs, such as fragments, may be produced, for example, by pepsin digestion of weight modulator peptide material. Other analogs, such as muteins, can be produced by standard site-directed mutagenesis of weight modulator peptide coding sequences. Analogs exhibiting "weight modulator activity" such as small
- 25 molecules, whether functioning as promoters or inhibitors, may be identified by known *in vivo* and/or *in vitro* assays.

In addition to recombinant expression of ob polypeptide, the present invention envisions and fully enables preparation of ob polypeptide, or fragments thereof,

09636647-101000

using the well known and highly developed techniques of solid phase peptide synthesis. The invention contemplates using both the popular Boc and Fmoc, as well as other protecting group strategies, for preparing ob polypeptide or fragments thereof. Various techniques for refolding and oxidizing the cysteine  
 5 side chains to form a disulfide bond are also well known in the art.

As mentioned above, a DNA sequence encoding weight modulator peptides as disclosed herein can be prepared synthetically rather than cloned. The DNA sequence can be designed with the appropriate codons for the weight modulator peptide amino acid sequences. In general, one will select preferred codons for the  
 10 intended host if the sequence will be used for expression. The complete sequence is assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge, *Nature*, **292**:756 (1981); Nambair et al., *Science*, **223**:1299 (1984); Jay et al., *J. Biol. Chem.*, **259**:6311 (1984).

15 Synthetic DNA sequences allow convenient construction of genes which will express weight modulator analogs or "muteins". Alternatively, DNA encoding muteins can be made by site-directed mutagenesis of native modulator genes or cDNAs, and muteins can be made directly using conventional polypeptide synthesis.

20 A general method for site-specific incorporation of unnatural amino acids into proteins is described in Christopher J. Noren, Spencer J. Anthony-Cahill, Michael C. Griffith, Peter G. Schultz, *Science*, **244**:182-188 (April 1989). This method may be used to create analogs of the ob polypeptide with unnatural amino acids.

The present invention extends to the preparation of antisense nucleotides and  
 25 ribozymes that may be used to interfere with the expression of the weight modulator proteins at the translational level. This approach utilizes antisense

nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a ribozyme.

- Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (See Weintraub, 1990;
- 5 Marcus-Sekura, 1988). In the cell, they hybridize to that mRNA, forming a double stranded molecule. The cell does not translate an mRNA in this double-stranded form. Therefore, antisense nucleic acids interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon will be particularly efficient,
- 10 since they are easy to synthesize and are likely to pose fewer problems than larger molecules when introducing them into weight modulator peptide-producing cells. Antisense methods have been used to inhibit the expression of many genes *in vitro* (Marcus-Sekura, 1988; Hambor et al., 1988).

- Ribozymes are RNA molecules possessing the ability to specifically cleave other
- 15 single stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and
- 20 cleave it (Cech, 1988). Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

- Investigators have identified two types of ribozymes, *Tetrahymena*-type and "hammerhead"-type (Hasselhoff and Gerlach, 1988). *Tetrahymena*-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to
- 25 eighteen-base sequences. The longer the recognition sequence, the more likely it is to occur exclusively in the target MRNA species. Therefore, hammerhead-type ribozymes are preferable to *Tetrahymena*-type ribozymes for inactivating a specific

mRNA species, and eighteen base recognition sequences are preferable to shorter recognition sequences.

The DNA sequences described herein may thus be used to prepare antisense molecules against and ribozymes that cleave mRNAs for weight modulator

- 5 proteins and their ligands, thus inhibiting expression of the *ob* gene, and leading to increased weight gain and adiposity.

The present invention also relates to a variety of diagnostic applications, including methods for detecting the presence of conditions and/or stimuli that impact abnormalities in body weight or adiposity, by reference to their ability to elicit the

10 activities which are mediated by the present weight modulators. As mentioned earlier, the weight modulator peptides can be used to produce antibodies to themselves by a variety of known techniques, and such antibodies could then be isolated and utilized as in tests for the presence of particular transcriptional activity in suspect target cells.

- 15 Antibody(ies) to the body weight modulators, *i.e.*, the *ob* polypeptide, can be produced and isolated by standard methods including the well known hybridoma techniques. For convenience, the antibody(ies) to the weight modulators will be referred to herein as Ab<sub>1</sub> and antibody(ies) raised in another species as Ab<sub>2</sub>.

- 20 According to the invention, *ob* polypeptide produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins, may be used as an immunogen to generate antibodies that recognize the *ob* polypeptide. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.

- 25 Various procedures known in the art may be used for the production of polyclonal antibodies to *ob* polypeptide a recombinant PTP or derivative or analog thereof. For the production of antibody, various host animals can be immunized by

injection with the ob polypeptide, or a derivative (*e.g.*, fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the ob polypeptide or fragment thereof can be conjugated to an immunogenic carrier, *e.g.*, bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward the ob polypeptide, or fragment, analog, or derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (1975, *Nature* 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030) or by transforming human B cells with EBV virus *in vitro* (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, *J. Bacteriol.* 159:870; Neuberger et al., 1984, *Nature* 312:604-608; Takeda et al., 1985, *Nature* 314:452-454) by splicing the genes from a mouse antibody molecule specific for an ob polypeptide together with genes from a human

antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described *infra*), since the human or humanized antibodies are much less likely  
 5 than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves.

According to the invention, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce ob polypeptide-specific single chain antibodies. An additional embodiment of the invention  
 10 utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for an ob polypeptide, or its derivatives, or analogs.

Antibody fragments which contain the idiotype of the antibody molecule can be  
 15 generated by known techniques. For example, such fragments include but are not limited to: the  $F(ab')_2$  fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the  $F(ab')_2$  fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

20 In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, *e.g.*, radioimmunoassay, ELISA (enzyme-linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels,  
 25 for example), western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the

0968647 1010000

5 present invention. For example, to select antibodies which recognize a specific epitope of an ob polypeptide, one may assay generated hybridomas for a product which binds to an ob polypeptide fragment containing such epitope. For selection of an antibody specific to an ob polypeptide from a particular species of animal, one can select on the basis of positive binding with ob polypeptide expressed by or  
10 isolated from cells of that species of animal.

15 In a specific embodiment, antibodies that agonize or antagonize the activity of ob polypeptide can be generated. Such antibodies can be tested using the assays described *infra* for identifying ligands.

25 In a specific embodiment, antibodies are developed by immunizing rabbits with synthetic peptides predicted by the protein sequence or with recombinant proteins made using bacterial expression vectors. The choice of synthetic peptides is made

after careful analysis of the predicted protein structure, as described above. In particular, peptide sequences between putative cleavage sites are chosen. Synthetic peptides are conjugated to a carrier such as KLH hemocyanin or BSA using carbodiimide and used in Freund's adjuvant to immunize rabbits. In order to

- 5 prepare recombinant protein, the *gex* vector can be used to express the polypeptide (Smith and Johnson, *supra*). Alternatively, one can use only hydrophilic domains to generate the fusion protein. The expressed protein will be prepared in quantity and used to immunize rabbits in Freund's adjuvant.

- The presence of weight modulator in cells can be ascertained by the usual
- 10 immunological procedures applicable to such determinations. A number of useful procedures are known. Three such procedures which are especially useful utilize either the receptor recognition factor labeled with a detectable label, antibody Ab<sub>1</sub> labeled with a detectable label, or antibody Ab<sub>2</sub> labeled with a detectable label. The procedures may be summarized by the following equations wherein the
- 15 asterisk indicates that the particle is labeled, and "WM" stands for the weight modulator:

$$A. WM^* + Ab_1 = WM^*Ab_1$$

$$B. WM + Ab^* = WMAb_1^*$$

$$C. WM + Ab_1 + Ab_2^* = Ab_1WMAb_2^*$$

- 20 The procedures and their application are all familiar to those skilled in the art and accordingly may be utilized within the scope of the present invention. The "competitive" procedure, Procedure A, is described in U.S. Patent Nos. 3,654,090 and 3,850,752. Procedure B is representative of the well known competitive assay techniques. Procedure C, the "sandwich" procedure, is described in U.S. Patent
- 25 Nos. RE 31,006 and 4,016,043. Still other procedures are known such as the "double antibody", or "DASP" procedure.

In each instance, the weight modulators form complexes with one or more antibody(ies) or binding partners and one member of the complex is labeled with a



detectable label. The fact that a complex has formed and, if desired, the amount thereof, can be determined by known methods applicable to the detection of labels.

It will be seen from the above, that a characteristic property of  $Ab_2$  is that it will react with  $Ab_1$ . This is because  $Ab_1$  raised in one mammalian species has been  
 5 used in another species as an antigen to raise the antibody  $Ab_2$ . For example,  $Ab_2$  may be raised in goats using rabbit antibodies as antigens.  $Ab_2$  therefore would be anti-rabbit antibody raised in goats. For purposes of this description and claims,  $Ab_1$  will be referred to as a primary or anti-weight modulator antibody, and  $Ab_2$  will be referred to as a secondary or anti- $Ab_1$  antibody.

10 The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to ultraviolet light, and others.

A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine and auramine. A particular detecting  
 15 material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate.

The weight modulators or their binding partners can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be  
 20 selected from  $^3H$ ,  $^{14}C$ ,  $^{32}P$ ,  $^{35}S$ ,  $^{36}Cl$ ,  $^{51}Cr$ ,  $^{57}Co$ ,  $^{58}Co$ ,  $^{59}Fe$ ,  $^{90}Y$ ,  $^{125}I$ ,  $^{131}I$ , and  $^{186}Re$ .

Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by  
 25 reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase,

$\beta$ -glucuronidase,  $\beta$ -D-glucosidase,  $\beta$ -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090; 3,850,752; and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.

- 5 A particular assay system that is to be utilized in accordance with the present invention, is known as a receptor assay. In a receptor assay, the material to be assayed is appropriately labeled and then certain cellular test colonies are inoculated with a quantity of both the labeled and unlabeled material after which binding studies are conducted to determine the extent to which the labeled material  
10 binds to the cell receptors. In this way, differences in affinity between materials can be ascertained.

- Accordingly, a purified quantity of the weight modulator may be radiolabeled and combined, for example, with antibodies or other inhibitors thereto, after which binding studies would be carried out. Solutions would then be prepared that  
15 contain various quantities of labeled and unlabeled uncombined weight modulator, and cell samples would then be inoculated and thereafter incubated. The resulting cell monolayers are then washed, solubilized and then counted in a gamma counter for a length of time sufficient to yield a standard error of <5%. These data are then subjected to Scatchard analysis after which observations and conclusions  
20 regarding material activity can be drawn. While the foregoing is exemplary, it illustrates the manner in which a receptor assay may be performed and utilized, in the instance where the cellular binding ability of the assayed material may serve as a distinguishing characteristic. In turn, a receptor assay will be particularly useful in the identification of the specific receptors to the present modulators, such as the  
25 *db* receptor.

A further assay useful and contemplated in accordance with the present invention is known as a "cis/trans" assay. Briefly, this assay employs two genetic constructs, one of which is typically a plasmid that continually expresses a

particular receptor of interest when transfected into an appropriate cell line, and the second of which is a plasmid that expresses a reporter such as luciferase, under the control of a receptor/ligand complex. Thus, for example, if it is desired to evaluate a compound as a ligand for a particular receptor, one of the plasmids  
5 would be a construct that results in expression of the receptor in the chosen cell line, while the second plasmid would possess a promoter linked to the luciferase gene in which the response element to the particular receptor is inserted. If the compound under test is an agonist for the receptor, the ligand will complex with the receptor, and the resulting complex will bind the response element and initiate  
10 transcription of the luciferase gene. The resulting chemiluminescence is then measured photometrically, and dose response curves are obtained and compared to those of known ligands. The foregoing protocol is described in detail in U.S. Patent No. 4,981,784 and PCT International Publication No. WO 88/03168, for which purpose the artisan is referred.

- 15 In a further embodiment of this invention, commercial test kits suitable for use by a medical specialist may be prepared to determine the presence or absence of predetermined transcriptional activity or predetermined transcriptional activity capability in suspected target cells. In accordance with the testing techniques discussed above, one class of such kits will contain at least the labeled weight  
20 modulator or its binding partner, for instance an antibody specific thereto, and directions, of course, depending upon the method selected, e.g., "competitive", "sandwich", "DASP" and the like. The kits may also contain peripheral reagents such as buffers, stabilizers, etc.

Accordingly, a test kit may be prepared for the demonstration of the presence or  
25 capability of cells for predetermined transcriptional activity, comprising:

- (a) a predetermined amount of at least one labeled immunochemically reactive component obtained by the direct or indirect attachment of the present weight modulator or a specific binding partner thereto, to a detectable label;
- (b) other reagents; and

(c) directions for use of said kit.

More specifically, the diagnostic test kit may comprise:

- (a) a known amount of the weight modulator as described above (or a binding partner) generally bound to a solid phase to form an immunosorbent, or in the alternative, bound to a suitable tag, or plural such end products, etc. (or their binding partners) one of each;
- (b) if necessary, other reagents; and
- (c) directions for use of said test kit.

In a further variation, the test kit may be prepared and used for the purposes stated above, which operates according to a predetermined protocol (e.g. "competitive", "sandwich", "double antibody", etc.), and comprises:

- (a) a labeled component which has been obtained by coupling the weight modulator to a detectable label;
- (b) one or more additional immunochemical reagents of which at least one reagent is a ligand or an immobilized ligand, which ligand is selected from the group consisting of:
  - (i) a ligand capable of binding with the labeled component (a);
  - (ii) a ligand capable of binding with a binding partner of the labeled component (a);
  - (iii) a ligand capable of binding with at least one of the component(s) to be determined; and
  - (iv) a ligand capable of binding with at least one of the binding partners of at least one of the component(s) to be determined; and
- (c) directions for the performance of a protocol for the detection and/or determination of one or more components of an immunochemical reaction between the weight modulator and a specific binding partner thereto.

In accordance with the above, an assay system for screening potential drugs effective to mimic or antagonize the activity of the weight modulator may be

prepared. The weight modulator may be introduced into a test system, and the prospective drug may also be introduced into the resulting cell culture, and the culture thereafter examined to observe any changes in the activity of the cells, due either to the addition of the prospective drug alone, or due to the effect of added quantities of the known weight modulator.

As stated earlier, the molecular cloning of the *ob* gene described herein has led to the identification of a class of materials that function on the molecular level to modulate mammalian body weight. The discovery of the modulators of the invention has important implications for the diagnosis and treatment of nutritional disorders including, but not limited to, obesity, weight loss associated with cancer and the treatment of diseases associated with obesity such as hypertension, heart disease and Type II diabetes. In addition, there are potential agricultural uses for the gene product in cases where one might wish to modulate the body weight of domestic animals. Finally, to the extent that one or more of the modulators of the invention are secreted molecules, they can be used biochemically to isolate their receptor using the technology of expression cloning. The discussion that follows with specific reference to the *ob* gene bears general applicability to the class of modulators that a part of the present invention, and is therefore to be accorded such latitude and scope of interpretation.

#### Therapeutic Implications

In the simplest analysis the *ob* gene determines body weight in mammals, in particular mice and man. The *ob* gene and, correspondingly, cognate molecules, appear to be part of a signaling pathway by which adipose tissue communicates with the brain and the other organs. It is believed that the *ob* polypeptide is itself a signaling molecule, *i.e.*, a hormone. Alternatively *ob* may be responsible for the generation of a metabolic signal, *e.g.*, a stimulating hormone or an enzyme that catalyzes activation or synthesis of a peptide or steroid hormone. The most important piece of information for distinguishing between these possibilities or considering alternative hypothesis, is the complete DNA sequence of the RNA and

its predicted protein sequence. Irrespective of its biochemical function the genetic data suggest that increased activity of *ob* would result in weight loss while decreased activity would be associated with weight gain. The means by which the activity of *ob* can be modified so as to lead to a therapeutic effect depends on its

5 biochemical function.

Administration of recombinant *ob* polypeptide can result in weight loss. Recombinant protein can be prepared using standard bacterial and/or mammalian expression vectors, all as stated in detail earlier herein. Reduction of *ob* polypeptide activity (by developing antagonists, inhibitors, or antisense molecules)

10 should result in weight gain as might be desirable for the treatment of the weight loss associated with cancer, AIDS or anorexia nervosa. Modulation of *ob* activity can be useful for reducing body weight (by increasing its activity) or increasing body weight (by decreasing its activity).

The *ob* polypeptide, or functionally active fragment thereof, or an antagonist

15 thereof, can be administered orally or parenterally, preferably parenterally. Because metabolic homeostasis is a continuous process, controlled release administration of *ob* polypeptide is preferred. For example, the polypeptide may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In one

20 embodiment, a pump may be used (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug*

25 *Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the

therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, supra, vol. 2, pp. 115-138 (1984)). Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)). In another embodiment, the

5 therapeutic compound can be delivered in a vesicle, in particular a liposome (see Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.)

- 10 In a further aspect, recombinant cells that have been transformed with the *ob* gene and that express high levels of the polypeptide can be transplanted in a subject in need of *ob* polypeptide. Preferably autologous cells transformed with *ob* are transplanted to avoid rejection; alternatively, technology is available to shield non-autologous cells that produce soluble factors within a polymer matrix that prevents
- 15 immune recognition and rejection.

Thus, the *ob* polypeptide can be delivered by intravenous, intraarterial, intraperitoneal, intramuscular, or subcutaneous routes of administration. Alternatively, the *ob* polypeptide, properly formulated, can be administered by nasal or oral administration. A constant supply of *ob* can be ensured by providing

20 a therapeutically effective dose (*i.e.*, a dose effective to induce metabolic changes in a subject) at the necessary intervals, *e.g.*, daily, every 12 hours, etc. These parameters will depend on the severity of the disease condition being treated, other actions, such as diet modification, that are implemented, the weight, age, and sex of the subject, and other criteria, which can be readily determined according to

25 standard good medical practice by those of skill in the art.

Alternatively, the *ob* gene could be introduced into human fat cells to develop gene therapy for obesity. Such therapy would be expected to decrease body weight. Conversely, introduction of antisense constructs into human fat cells

would reduce the levels of active *ob* polypeptide and would be predicted to increase body adiposity.

- If *ob* is an enzyme, strategies have begun to be developed for the identification of the substrate and product of the catalyzed reaction that would make use of the recombinant protein. The rationale for this strategy is as follows: If *ob* is an enzyme that catalyzes a particular reaction in adipose tissue, then fat cells from *ob* mice should have high levels of the substrate and very little product. Since it is hypothesized that *db* mice are resistant to the product of this reaction, fat cells from *db* mice should have high levels of the reaction product. Thus, comparisons of lipid and peptide extracts of *ob* and *db* adipose tissue using gas chromatography or other chromatographic methods should allow the identification of the product and substrate of the key chemical reaction. The prediction would be that the recombinant *ob* protein would catalyze this reaction. The product of this reaction would then be a candidate for a signaling molecule that modulates body weight.
- As noted above, the functional activity of the *ob* polypeptide can be effected transgenically,, *e.g.*, by gene therapy. In this respect, a transgenic mouse model can be used. The *ob* gene can be used in complementation studies employing transgenic mice. Transgenic vectors, including viral vectors, or cosmid clones (or phage clones) corresponding to the wild type locus of candidate gene, can be constructed using the isolated *ob* gene. Cosmids may be introduced into transgenic mice using published procedures (Jaenisch, *Science* **240**, 1468-1474, 1988). The constructs are introduced into fertilized eggs derived from an intercross between F1 progeny of a C57BL/6J *ob/ob* X DBA intercross. These crosses require the use of C57BL/6J *ob/ob* ovarian transplants to generate the F1 animals. DBA/2J mice are used as the counterstrain because they have a nonagouti coat color which is important when using the ovarian transplants. Genotype at the *ob* loci in cosmid transgenic animals can be determined by typing animals with tightly linked RFLPs or microsatellites which flank the mutation and which are polymorphic between the progenitor strains. Complementation will be



demonstrated when a particular construct renders a genetically obese F2 animal (as scored by RFLP analysis) lean and nondiabetic. Under these circumstances, final proof of complementation will require that the *ob/ob* or *db/db* animal carrying the transgene be mated to the *ob/ob* or *db/db* ovarian transplants. In this cross, all N2

5 animals which do not carry the transgene will be obese and insulin resistant/diabetic, while those that do carry the transgene will be lean and have normal glucose and insulin concentrations in plasma. In a genetic sense, the transgene acts as a suppressor mutation.

- Alternatively, *ob* genes can be tested by examining their phenotypic effects when
- 10 express in antisense orientation in wild-type animals. In this approach, expression of the wild type allele is suppressed, which leads to a mutant phenotype. RNA-RNA duplex formation (antisense-sense) prevents normal handling of mRNA, resulting in partial or complete elimination of wild-type gene effect. This technique has been used to inhibit Tk synthesis in tissue culture and to produce
- 15 phenotypes of the Kruppel mutation in *Drosophila*, and the shiverer mutation in mice (Izant and Weintraub, *Cell* **36**, 1007-1015, 1984; Green et al., *Annu. Rev. Biochem.* **55**, 569-597, 1986; Katsuki et al., *Science* **241**, 593-595, 1988). An important advantage of this approach is that only a small portion of the gene need be expressed for effective inhibition of expression of the entire cognate mRNA.
- 20 The antisense transgene will be placed under control of its own promoter or another promoter expressed in the correct cell type, and placed upstream of the SV40 poly A site. This transgene will be used to make transgenic mice. Transgenic mice will also be mated ovarian transplants to test whether *ob* heterozygotes are more sensitive to the effects of the antisense construct.
- 25 In the long term, the elucidation of the biochemical function of the *ob* gene product (the *ob* polypeptide or protein) is useful for identifying small molecule agonists and antagonists that affect its activity.

### Diagnostic Implications

The human cDNA clones that have recently been isolated have been sequenced as presented herein. This facilitates the determination of the complete sequence of the human gene (see Figure 20). DNA sequences from the introns of the human *ob* gene have been obtained (Figure 20), and these have been used to prepare PCR primers to PCR amplify the coding sequence of the *ob* gene from human genomic DNA so as to identify mutations or allelic variants of the *ob* gene, all in accordance with protocols described in detail earlier herein. Specific PCR primers for amplifying human genomic *ob* are described in a specific Example, *infra*.

- 10 The current hypothesis is that heterozygous mutations in the *ob* gene will be associated with mild/moderate obesity while homozygous mutations would be associated with severe DNA sequence based diagnostic tests obesity. If this is true, it would allow the ascertainment of people at risk for the development of obesity and make possible the application of drug treatment and/or lifestyle
- 15 changes before an increased body weight is fully developed.

Alternatively, the presence of microsatellites that segregate with mutant forms of human *ob* can be used for diagnosis. Various PCR primers, including those based on the nucleotide sequence provided in Figure 20A, can be used in this respect.

- The *ob* gene may also be useful diagnostically for measurements of its encoded
- 20 RNA and protein in nutritional disorders. It will be of importance to know, in a particular nutritional disorder, whether *ob* RNA and/or protein is unregulated or downregulated. Thus, if an obese person has increased levels of *ob*, it would appear that the problem is downstream of *ob*, while if *ob* is reduced, it would appear that inappropriately low levels of *ob* may be cause of obesity (whether or
  - 25 not the defect is in the *ob* gene). Conversely, if a cancer or AIDS patient who lost weight had elevated levels of *ob*, it may be concluded that inappropriately high expression of *ob* is responsible for the weight loss.

The cloned human cDNA will be of use for the measurement of the levels of human *ob* RNA. In addition, recombinant human protein will be prepared and used to develop immunoassays to enable measurement of the fat and perhaps plasma levels of the *ob* protein.

5

#### Agricultural Applications

The *ob* gene can also be isolated from domestic animals, and the corresponding *ob* polypeptide obtained thereby. In a specific example, *infra*, the a probe derived from the murine *ob* gene hybridizes to corresponding homologous coding sequences from a large number of species of animals. As discussed for human therapies, recombinant proteins can also be prepared and administered to domestic animals. Administration of the polypeptide can be implemented to produce leaner food animals, such as beef cattle, swine, poultry, sheep, etc. Preferably, an autologous *ob* polypeptide is administered, although the invention contemplates administration of anti-autologous polypeptide as well. Since the *ob* polypeptide consists of approximately 160 amino acid residues, it may not be highly immunogenic. Thus, administration of non-autologous polypeptide may not result in an immune response.

Alternatively, the introduction of the cloned genes into transgenic domestic animals would allow one to potentially decrease body weight and adiposity by overexpressing an *ob* transgene. The simplest means of achieving this would be to target an *ob* transgene to fat using its own or another fat specific promoter.

Conversely, increases in body fat might be desirable in other circumstances such as for the development of Kobe beef or fatty liver to make foie gras. This could be accomplished by targeting an antisense *ob* transgene to fat, or by using gene knockout technology. Alternatively, where an increase in body weight at percentage of fat is desired, an inhibitor or antagonist of the *ob* polypeptide can be administered. Such inhibitors or antagonists include, but are not limited to,

antibodies reactive with the polypeptide, and fragments of the polypeptide that bind but do not activate the ob receptor, *i.e.*, antagonists of ob polypeptide.

### The ob Receptor

Development of small molecule agonists and antagonists of the *ob* factor will be greatly facilitated by the isolation of its receptor. This can be accomplished by preparing active ob polypeptide and using it to screen an expression library using standard methodology. Receptor binding in the expression library can be tested by administering recombinant polypeptide prepared using either bacterial or mammalian expression vectors, and observing the effects of short term and continuous administration of the recombinant polypeptide on the cells of the expression library, or by directly detecting binding of ob polypeptide to the cells.

As it is presently believed that the ob receptor is likely to be located in the hypothalamus and perhaps liver, preferably cDNA libraries from these tissues will be constructed in standard expression cloning vectors. These cDNA clones would next be introduced into COS cells as pools and the resulting transformants would be screened with active ligand to identify COS cells expressing the ob receptor. Positive clones can then be isolated so as to recover the cloned receptor. The cloned receptor would be used in conjunction with the *ob* ligand (assuming it is a hormone) to develop the necessary components for screening of small molecule modulators of *ob*.

Once a recombinant which expresses the ob receptor gene sequence is identified, the recombinant *ob* receptor can be analyzed. This is achieved by assays based on the physical or functional properties of the *ob* receptor, including radioactive labelling of the receptor followed by analysis by gel electrophoresis, immunoassay, ligand binding, etc. Furthermore, antibodies to the ob receptor could be generated as described above.

- 20 software programs available in the art.

20 software programs available in the art.

- By providing an abundant source of recombinant *ob* polypeptide, and the opportunity to isolate the *ob* receptor (*i.e.*, the *db* gene product), the present invention enables quantitative structural determination of the active conformation of the *ob* polypeptide and the *ob* receptor, or domains thereof. In particular, 25 enough material is provided for nuclear magnetic resonance (NMR), infrared (IR), Raman, and ultraviolet (UV), especially circular dichroism (CD), spectroscopic analysis. In particular NMR provides very powerful structural analysis of

- molecules in solution, which more closely approximates their native environment (Marion et al., 1983, Biochem. Biophys. Res. Comm. 113:967-974; Bar et al., 1985, J. Magn. Reson. 65:355-360; Kimura et al., 1980, Proc. Natl. Acad. Sci. U.S.A. 77:1681-1685). Other methods of structural analysis can also be
- 5 employed. These include but are not limited to X-ray crystallography (Engstrom, A., 1974, Biochem. Exp. Biol. 11:7-13).

- More preferably, co-crystals of ob polypeptide and ob receptor can be studied. Analysis of co-crystals provides detailed information about binding, which in turn allows for rational design of ligand agonists and antagonists. Computer modeling
- 10 can also be used, especially in connection with NMR or X-ray methods (Fletterick, R. and Zoller, M. (eds.), 1986, Computer Graphics and Molecular Modeling, in *Current Communications in Molecular Biology*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).

- Identification and isolation of a gene encoding an ob receptor of the invention
- 15 provides for expression of the receptor in quantities greater than can be isolated from natural sources, or in indicator cells that are specially engineered to indicate the activity of a receptor expressed after transfection or transformation of the cells. According, in addition to rational design of agonists and antagonists based on the structure of ob polypeptide, the present invention contemplates an alternative
- 20 method for identifying specific ligands of ob receptor using various screening assays known in the art.

- Any screening technique known in the art can be used to screen for *ob* receptor agonists or antagonists. The present invention contemplates screens for small molecule ligands or ligand analogs and mimics, as well as screens for natural
- 25 ligands that bind to and agonize or antagonize activates *ob* receptor *in vivo*.

Knowledge of the primary sequence of the receptor, and the similarity of that sequence with proteins of known function, can provide an initial clue as the

inhibitors or antagonists of the protein. Identification and screening of antagonists is further facilitated by determining structural features of the protein, *e.g.*, using X-ray crystallography, neutron diffraction, nuclear magnetic resonance spectrometry, and other techniques for structure determination. These techniques  
 5 provide for the rational design or identification of agonists and antagonists.

Another approach uses recombinant bacteriophage to produce large libraries.

Using the "phage method" (Scott and Smith, 1990, Science 249:386-390; Cwirla, et al., 1990, Proc. Natl. Acad. Sci., 87:6378-6382; Devlin et al., 1990, Science, 249:404-406), very large libraries can be constructed ( $10^6$ - $10^8$  chemical entities).

- 10 A second approach uses primarily chemical methods, of which the Geysen method (Geysen et al., 1986, Molecular Immunology 23:709-715; Geysen et al. 1987, J. Immunologic Method 102:259-274) and the recent method of Fodor et al. (1991, Science 251, 767-773) are examples. Furka et al. (1988, 14th International Congress of Biochemistry, Volume 5, Abstract FR:013; Furka, 1991, Int. J. Peptide Protein Res. 37:487-493), Houghton (U.S. Patent No. 4,631,211, issued  
 15 December 1986) and Rutter et al. (U.S. Patent No. 5,010,175, issued April 23, 1991) describe methods to produce a mixture of peptides that can be tested as agonists or antagonists.

- In another aspect, synthetic libraries (Needels et al., 1993, "Generation and  
 20 screening of an oligonucleotide encoded synthetic peptide library," Proc. Natl. Acad. Sci. USA 90:10700-4; Lam et al., International Patent Publication No. WO 92/00252, each of which is incorporated herein by reference in its entirety), and the like can be used to screen for *ob* receptor ligands according to the present invention. With such libraries, receptor antagonists can be detected using cell that  
 25 express the receptor without actually cloning the *ob* receptor (Lam et al., *supra*).

Alternatively, assays for binding of soluble ligand to cells that express recombinant forms of the *ob* receptor ligand binding domain can be performed.

The screening can be performed with recombinant cells that express the ob receptor, or alternatively, using purified receptor protein, *e.g.*, produced

5 recombinantly, as described above. For example, the ability of labeled, soluble or solubilized ob receptor that includes the ligand-binding portion of the molecule, to bind ligand can be used to screen libraries, as described in the foregoing references.

### EXAMPLE SECTION

10 The following outlines the method used to identify the genetic material that is exemplary of the present invention. This endeavor comprises four sequential steps: A) Genetic Mapping, B) Physical Mapping, C) Candidate Gene Isolation, and D) Mutation detection. Following confirmation that the murine gene in object  
was isolated (Step D), the homologous human gene was sought, and both the  
15 murine and human genes and putative proteins were characterized. The steps are summarized in greater detail, below.

### A. Genetic Mapping

The *ob* mutation was segregated in genetic crosses and standard linkage analysis was used to position the mutation relative to RFLPs (restriction fragment length polymorphisms). These data placed the *ob* gene in an  $\sim 5\text{cM}$  interval on proximal mouse chromosome 6. (5cM is a measurement of genetic distance corresponding to 5 apparent genetic crossovers per 100 animals.) A total of 771 informative meioses were generated and used in subsequent genetic mapping (Friedman et al. *Genomics* 11: 1054-1062, 1991). The genetic loci that were mapped relative to *ob* were all previously published. The two closest RFLPs described were defined by probes derived from the carboxypeptidase and *met* oncogene genes.



The genetic resolution of the experiments described above was inadequate to clone *ob*, principally because none of the genetic markers were in tight linkage. In order to identify the requisite tightly linked RFLPs, additional probes were isolated and the genetic cross was expanded. A method known as chromosome

5 microdissection was used to isolate random pieces of DNA from proximal mouse chromosome 6 (Bahary et al., *Mammalian Genome* 4: 511-515, 1993). Individual cloned probes were tested for tight linkage to *ob*. On the basis of these studies one probe, D6Rck13, also termed psd3, was selected for further analysis owing to its genetic proximity to *ob*.

- 10 This probe was used to genotype 835 *ob* progeny from interspecific and intersubspecific crosses, which indicated that D6Rck13 is nonrecombinant in all 835 animals as reported in Bahary et al. In the course of physical mapping, a new polymorphic marker was identified from a cosmid subclone derived from YAC
- 15 53A6. This new marker was positioned between D6Rck13 and the *ob* gene and was used to genotype the additional 771 informative meioses from intraspecific intercross and backcross. A single animal #167 was identified to bear a recombination crossover between *ob* and D6Rck39. These studies indicated that D6Rck39/D6Rck13 is ~0.06 cM from *ob*. An additional probe, Pax-4, was identified that was .12 cM proximal to *ob*. Pax-4 was recombinant in two
- 20 animals; #111 and 420. Pax-4 is a pseudogene that was previously mapped to proximal mouse chromosome 6 by Gruss and co-workers (Gruss et al. *Genomics* 11:424-434, 1991). On this basis, it was determined that the *ob* gene resides in the ~ 0.2cM interval between Pax-4 and D6Rck13. This led to efforts to clone the interposing DNA in an effort to isolate *ob*.

## 25 B. Physical Mapping

The cloning of the DNA in this interval made use of yeast artificial chromosomes (YACs), a relatively new cloning vector that allows the cloning of long stretches of contiguous DNA often more than 1 million base pairs in length.

This was accomplished by preparing purified DNA probes and using them to isolate the corresponding YACs. These YACs (#8, 16, 107 and 24) were isolated and initially characterized, and on the basis of the resulting analyses it was

20 A PCR assay for these two ends, *aad*(pICL) and *adu*(+) was developed and used for isolating moire YACs and P1 clones to continue physical mapping. The important P1 clones isolated by this effort included 498, 499, 500 (isolated using a probe derived from *aad*(pICL)) and 322, 323 and 324 (using a probe from *adu*(+)).

25 In the meantime, YACs isolated by D6Rck13 (53A6, 25A8, 25A9, 25A10) were characterized. These studies determined that 53A6 extended furthest proximally toward the *aad* YAC. The size of the gap between 53A6 and *aad* was determined ~70 kB. The key end of 53A6, 53(pICL) was then used to screen three available YAC libraries and a P1 library. A critical P1 clone, 325, was isolated. This P1

clone overlapped with the P1 clones isolated by *aad*(pICL) as described above, and therefore served to close the gap between 53(pICL) and *aad*(pICL). As a result, the whole contig, containing YACs and P1 clones, of ~2.5 million base pairs in length, and which spanned Pax4, 16M(+), *adu*(+), *aad*(pICL), 53(pICL),  
 5 D6Rck39 and D6Rck13, was cloned. By carefully mapping the sites of recombination apparent in animal #111 and 167, it was concluded that *ob* was situated in a 400 kB interval. To provide a working DNA source for isolating the *ob* gene, about 500 kB covering this nonrecombination region was isolated in a total of 24 P1 clones. These P1 clones, including 322 and 323, which later were  
 10 proved to be useful clones, were used for exon trapping.

The physical map of the portion of the chromosome carrying *ob* is shown in Figure 7A. Figure 7B represents the YAC contig. Figure 7C represents the P1 contig.

### C. Isolation of Candidate Genes

15 The method used to isolate genes in this interval was exon trapping. This method used a commercial vector to identify exon DNA (*i.e.*, coding sequences) by selecting for functional splice acceptor and donor sequences in genomic DNA introduced into a test construct. The DNA from these P1s were grown and subcloned into the exon trapping vector. These clones were short inserts cloned  
 20 into a Bluescript vector. Each clone was PCR amplified with PCR primers corresponding to plasmid sequences that flanked the insert. The PCR amplification was performed directly on the bacteria that carried the plasmid. The reactions were set up using a Biomek robot. The PCR products were electrophoresed on a 1% agarose gel in TBE buffer that contained ethidium  
 25 bromide. The exon trapping technique was modified to eliminate contaminating *E. coli* DNA from the P1 clones, and to screen out the abundant artifactual exons, which exceeded 80-90% of the putative exons trapped. The exon trapping vector includes HIV sequences; a short segment of these vector sequences corresponds to this artifact.

The exon trapping experiment was performed using various P1 clones. Exon trapping products were then amplified by PCR, selected, and sequenced. Sequences of putative "exons" were compared with those in Genbank using the Blast computer program. About 15 exons were selected for further examination

5 by RT-PCR, Northern analysis, and zoo blot for the presence of corresponding RNA or conservative sequences. Seven of the 15 putative exons, 325-2, 323-9, 322-5, D1-F7, 1H3, and 2G7, were found to encode an RNA transcript. 325-2 is a testis specific gene; 323-8 and 323-9 are likely two exons from the same gene expressed mainly in brain and kidney. 1H3 and 322-5 represent two low level

10 brain transcripts. D1-F7 is an exon from a previously cloned gene, inosine monophosphate dehydrogenase (IMPDH), which has ubiquitous expression pattern. None of these genes appeared to encode *ob*. 2G7, which is the *ob* exon, is discussed further below.

After three unsuccessful efforts to exon trap the *ob* gene, another attempt was

15 made by pooling DNA from all the P1s from the critical *ob* region. These included P1s: 258, 259, 322, 323, 324, 325, 498, 499, 500, 653, 654 and others. Thereafter P1s 258, 260, 322, 498 and 499 were subcloned into the exon trapping vector, and subsequently several plates were prepared with bacterial clones, each of which carried a putative exon. Approximately 192 clones representing putative

20 *ob* candidates were obtained. As noted above, a consistent artifact such that many of the isolates contained two trapped exons derived from the vector was observed. Thus, clones were identified both by their size and the fact that hybridization of DNA probes corresponding to this artifact hybridized to the corresponding bands on a Southern blot of the gel. In this way, 185 out of 192 clones were excluded

25 from further evaluation. Exclusion of the artifacts on the basis of size alone was not possible, as this could have, in the end, led to exclusion of the exon corresponding to *ob*.

Thus, of the 192 exons, a total of seven exons were selected for further study. Templates for sequencing the seven exons were prepared, and sequencing was

performed. The sequences for the 7 exons were analyzed and it was found that 4 were identical and one was an apparent artifact. In particular, clone 1D12 contained the "HIV sequence," *i.e.*, the artifact band. This left three exons for further analysis: 1F1, 2G7 and 1H3. 1F1 was eliminated because it mapped  
 5 outside the critical region. PCR primers for both 1H3 and 2G7 were selected and synthesized.

The sequence of the exon on 2G7 was determined, and is shown in Figure 10 (SEQ ID NO:7). PCR primers for 2G7 were selected and synthesized. The portions of the sequence corresponding to the PCR primers are underlined. The  
 10 primers used were:

5' CCA GGG CAG GAA AAT GTG (T<sub>m</sub> = 60.0) (SEQ ID NO:8)  
 3' CAT CCT GGA CTT TCT GGA TAG G (T<sub>m</sub> = 60.0) (SEQ ID NO:9)

These primers amplified genome DNA with PCR conditions as follows: 25-30 cycles at 55° annealing x 2', 72° extension x 2', 94° denaturation x 1' in standard  
 15 PCR buffer. These primers were also used to generate a labeled probe by including <sup>32</sup>P dCTP in the PCR reaction with a corresponding reduction in the amount of cold dCTP.

A RT PCR was performed on a variety of tissue RNAs and it was concluded that 2G7 was expressed exclusively in white fat among the tissues examined (Figure  
 20 11A). Thereafter, <sup>32</sup>P-labelled 2G7 was hybridized to a Northern blot of tissue RNAs (Figure 11B) and showed that its RNA was expressed at high level in fat tissue but was either not expressed or expressed at very low levels in all other tissues (where the signals may be the result of fat contaminating the tissue preparations). Ten µg of total RNA from each of the tissues listed was  
 25 electrophoresed on an agarose gel with formaldehyde. The probe was hybridized at 65° in a standard hybridization buffer, Rapid Hype (Amersham). The size of

the RNA was approximately 4.9 kB. At this point 2G7 was considered to be a viable candidate gene for *ob* and was analyzed further.

#### D. Mutation Detection

In order to confirm that 2G7 encoded the *ob* gene, it was necessary to demonstrate differences in the levels of RNA expression of DNA sequence of this gene in mutant as compared to wild type animals. Two separate mutations of the *ob* gene are available for study, C57BL/6J *ob/ob* (1J) and Ckc/Smj *ob/ob* (2J). These will be referred hereinafter as 1J and 2J, respectively. (Informal nomenclature is used to refer to the mouse strains studied. Throughout this specification and in the drawings, it will be understood that C57BL/6J refers to C57BL/6J +/+; CKC/smj refers to SM/Ckc-+<sup>Dac</sup>-+/+; CKC/smj *ob/ob* refers to SM/Ckc-+<sup>Dac</sup>-*ob*<sup>2J</sup>/*ob*<sup>2J</sup>). RNA was prepared from fat tissue that had been isolated from 1J, 2J, and control animals. Total RNA for each sample was treated with DNase and then reverse transcribed using oligo-dT as a primer and reverse transcriptase. The resulting single stranded cDNA was then PCR amplified either with the 2G7 primers (conditions shown above) for the lower band or commercially available actin primers for the upper band. The RT PCR products were run on a 1% agarose TBE gel that was stained with ethidium bromide (Figure 12A). Using RT-PCT it was found that while 2G7 mRNA was expressed in 1J and all the other control mice, it was completely missing in 2J mouse. No signal was detected after 30 cycles of amplification. This experiment provided direct evidence that 2G7 corresponded to an exon from the *ob* gene.

Since 2J mutation is relatively recent and is maintained as a coisogenic strain, this result was the first available evidence that indicated that 2G7 is an exon from the *ob* gene. The mutation is likely located in the promoter region which leads to total abortion of the mRNA synthesis. The presence of signal in 1J mouse in this RT-PCT experiment suggested that 1J might carry a point mutation which does not result in a gross change in size of the RNA sample. In addition, 2G7 mRNA was absent, when tested by RT PCR, from four additional 2J animals.

This result was confirmed on a Northern blot (Figure 12B). Fat cell RNA was prepared from each of the strains (C57Bl/6J, 1J, CKC/smj, and 2J). Ten  $\mu$ g of these RNAs were run out. The blot was probed with the 2G7 probe that was PCR labeled, by amplification of the material, i.e., band, in Figure 11 using  $^{32}$ P-dCTP in the PCR reaction. Actin is a control for the amount of RNA loaded. The actin signal is fairly similar in all of the samples. The *ob* signal is absent in brain because the mRNA is specific to fat cells.

The results of the Northern analysis confirm that 2G7 RNA was absent in 2J mice. The *ob* RNA is absent in the CKC/smj *ob/ob* mice because in this obese mutant strain the gene is disrupted such that no RNA is made. In addition, the level of 2G7 RNA was increased  $\sim$ 10-20 fold in 1J as well as *db/db* fat. These results are compatible with the hypothesis that *ob* either encodes circulating hormone or is responsible for the generation of a signal from fat cells that modulates body weight. These results supported the conclusion that 2G7 is the *ob* gene and predicted that 1J mice have a point mutation, probably a nonsense mutation leading to a premature translation termination.

These Northern results have been replicated using fat cell RNA preparations from four different 2J animals (Figure 13). In this assay, *ap2* is a fat-specific transcript that was used as a control much the same as actin in Figure 12B. There is no significance to the varying density of the *ap2* band. *ap2* was labeled by designing PCR primers from the published *ap2* sequence. The RT PCR products of fat cell RNA were then relabeled using the same protocol for PCR labeling. This analysis demonstrates the presence of *ob* mRNA in normal homozygous or heterozygous animals, and its absence from 2J mutant animals.

The mutation has been identified in 1J mice. The mutation is a C to T base change that results in change of an arginine to an apparent premature stop codon at amino acid 108, and in all likelihood accounts for the 1J mutation (Figure 14)

despite high level expression of the *ob* mRNA (see Figure 12 and 13, C57BL/6J ob/ob lanes).

More recently, Southern blots have been used to conclude that the 2J mutation is the result of a detectable DNA change at the 5' end of *ob* that appears to

- 5 completely abolish RNA expression. The exact nature of this possible rearrangement remains to be determined.

A genomic Southern blot of DNA from the CKC/smj (SM/Ckc-+<sup>Dac</sup>) and C57BL/6J mice using four different restriction endonucleases was performed in order to determine whether the mutant *ob* yielded a unique fragment pattern

- 10 (Figure 15A). Approximately 10  $\mu$ g of DNA (derived from genomic DNA prepared from liver, kidney, or spleen) was restriction digested with the restriction enzyme indicated. The DNA was then electrophoresed in a 1% agarose TBE gel. The DNA was transferred to an imobilon membrane and hybridized to the PCR labeled 2G7 probe. The key band is the uppermost band in the BglII digest for the
- 15 CKC/smj ob/ob (SM/Ckc-+<sup>DAC</sup> ob<sup>2J</sup>/ob<sup>2J</sup>) DNA. This band is of higher molecular weight than in the other strain, indicating a mutation in this strain.

Figure 15B is a southern blot of a BglII digest of genomic DNA from the progeny of an ob<sup>2J</sup>/+ x ob<sup>2J</sup>/+ cross. Some of the DNAs have only the upper band, some only the lower band, and some have the both bands. The animals with only the

20 upper band are allo-obese, *i.e.*, ob<sup>2J</sup>/ob<sup>2J</sup>. These data show that the polymorphism (*i.e.*, mutation) shown in Figure 15A segregates in a genetic sense.

#### cDNA Cloning and Sequence Determination of *ob*

Using the labeled 2G7 PCR probe, a total of 50 mouse cDNA clones from a murine fat cell  $\lambda$ gt11 cDNA library (Clontech 5'-STRETCH cDNA from

- 25 testicular fat pads of Swiss mice, #ML3005b), and thirty cross hybridizing human cDNA clones from a human fat cell  $\lambda$ gt10 cDNA library (Clontech 5'-STRETCH cDNA from abdomen #HL1108a) were isolated. Library screening was performed



using the plaque lift procedure. The filters from the plaque lift were denatured using the autoclave method. The filters were hybridized in duplicate with the PCR labeled 2G7 probe (Rapid Hybe buffer, 65°C, overnight). After a 2-4 hour prehybridization, the filters were washed in 2x SSC, 2% SDS, twice for 30 minutes at 65°C and exposed to SRY Llim. Duplicate positives were plaque purified. Plaque purified phage were PCR amplified using commercially available vector primers, *e.g.*,  $\lambda$ gt10 and  $\lambda$ gt11. The resulting PCR products corresponded to the cDNA insert for each phage with a small amount of vector sequence at either end. The bands were gel purified and sequenced using the ABI automated sequencer and the vector primers to probe the DNA polymerase.

The raw sequencing data were then manually examined base by base to correct mishearing from the computer program. As the correct sequence became available, the downstream primers were synthesized and used to continue sequencing. Such experiments were repeated until each available cDNA clone was sequenced and synthesized into a contig. To date, ~3000 base pairs from the 5' end of the mRNA has been compiled. One of the cDNA clones extended to the 5' end of the mRNA since its sequence was identical to that of the 5' RACE product of fat tissue RNA (data not shown).

The sequence data revealed that there is a 167 amino acid open reading frame (Figure 1). A Kozak translation initiation consensus sequence was present with an adenosine residue three bases upstream of the ATG. Two classes of cDNA were found differing by inclusion or exclusion of a single glutamine codon. This residue is found in a position immediately 3' to the splice acceptor of the 2G7 exon. Since the CAG codon of glutamine includes a possible AG splice acceptor sequence, it appears that there is slippage at the splice acceptor site with an apparent 3 base pairs deletion in a subset of the cDNA, as shown below.

5                    ser   val  
ag CAG TCG GTA (without glutamine)                    (SEQ ID NO:17)  
                     ↑  
(splice acceptor site)

A putative N-terminal signal sequence was detected, the signal cleavage site of which is predicted to be carboxy terminal to the alanine residue at amino acid position 21. This putative signal sequence was confirmed by application of a computer algorithm to the method of von Heijne (*Nucl. Acids Res.* **14**, 4683, 1986). Using this technique, the most probable signal sequence was identified in the polypeptide coding region corresponding to amino acids 1-23, having the sequence:

MCWRPLCRFLWLWSYLSYVQA ↑ VP (SEQ ID NO:10)

in which the arrow indicates the putative signal sequence cleavage site. The rest of the amino acid sequence was largely hydrophilic and did not have any notable structural motifs or membrane spanning domains other than the N-terminal signal sequence. Specifically, we did not find consensus sequences for N-linked glycosylation or dibase amino acid sequences indicative of protein cleavage in the predicted processed protein (Sabatini and Adesnik, *The metabolic basis of inherited disease*, C.V. Scriver et al. eds., McGraw-Hill: New York, pp. 177-223). Database search using Blast and Block programs did not identify any homologous sequence.

Human fat tissue RNA was analyzed on Northern blot, RNA species of similar size to the mouse *ob* gene was detected. Sequencing and analysis of cDNA clones revealed that human *ob* also encodes 167 amino acid polypeptide (Figures 2 and 3). Two classes of cDNA with or without three base pairs deletion were found in human as well (Figure 6). The mouse and human *ob* genes were highly homologous in the predicted coding region, but had only 30% homology in the available 3' and 5' untranslated regions. An N-terminal signal sequence was also present in the human *ob* polypeptide. Comparison of the human and mouse *ob* polypeptide sequences showed that the two molecules share an overall 84% identity at amino acid level (Figure 4). The N-termini of the mature proteins from both species share even higher homology, with only four conservative and three nonconservative amino acid substitutions among the N-terminal 100 amino acid residues.

Genomic DNA was isolated from mouse, rat, rabbit, vole, cat, cow, sheep, pig, human, chicken, eel, and drosophila, and restriction digested with EcoR1. The digests were electrophoresed on 1% agarose TBE gel. DNA was transferred to an imobilon membrane and probed with the PCR labeled 2G7 probe. The filter was hybridized at 65°C and washed with 2x SSC, 0.2% SDS at 65°C twice for twenty minutes each wash, *i.e.*, there were two buffer changes. These data indicate that *ob* is conserved among vertebrates (Figure 16). Note in this regard that there is a 2+ signal in eel DNA; eel is a fish.

In summary, available evidence suggests that body weight and adiposity are physiologically controlled. Seven years ago efforts began to identify two of the key components of this system: the *ob* and *db* genes. As shown in this example, the *ob* gene has now been identified as a fat specific gene that plays a key role in regulating body weight. The product of this gene, which is most probably a secreted hormone, will have important implications for the diagnosis and treatment of nutritional disorders in man and non-human animals.

EXAMPLE: Expression of *ob* In Bacteria

Both murine and human cDNAs encoding *ob* have been cloned into a pET-15b expression vector (Novagen). This vector contains a T7 promoter in conjunction with a lac operator, and expresses a fusion protein containing a histidine tag (His-  
 5 Tag) and a thrombin cleavage site immediately upstream of the coding sequence insertion site (Figure 17) (SEQ ID No:11).

The mouse and human cDNAs were modified such that the alanine at the end of the signal sequence was turned into an NdeI site, as was a separate sequence in the 3' region. Insertion of the NdeI site was accomplished using PCR with novel  
 10 primers:

Mnde-5' (murine five prime primer):

CTTATGTTCA TATGGTGCCG ATCCAGAAAG TC (SEQ ID NO:12)

Mnde-3' (murine three prime primer):

TCCCTCTACA TATGTCTTGG GAGCCTGGTG GC (SEQ ID NO:13)

15 Hnde-5' (human five prime primer):

TCTATGTCCA TATGGTGCCG ATCCAAAAAG TC (SEQ ID NO:14)

Hnde-3' (human three prime primer):

TTCCTTCCCA TATGGTACTC CTTGCAGGAA GA (SEQ ID NO:15)

The primers contain a 6-base pair mismatch in the middle that introduces NdeI  
 20 restriction sites at each end of the PCR fragment. Phage carrying either the mouse or human cDNA were PCR amplified using those primers. The PCR product was digested with NdeI and gel purified on a 1% low melting point agarose gel. The gel purified bands were subcloned into the pET vector. The resulting plasmids were sequenced to ensure that mutations were not introduced  
 25 during the PCR amplification step of cloning. Constructs for the human and murine cDNA that encodes and that lacks glutamine 49 have been prepared. In particular, pET 15b constructs containing either the human or the mouse *ob* coding sequence, minus signal sequence and fused to a Hig-Tag, have been made using a PCR cloning method. The constructs have been sequenced to ensure no sequence

errors were introduced into the coding region of the *ob* gene during the PCR amplification step.

Two resultant plasmid constructs, pETM9 and pETH14, were selected to transform a bacterial expression host. Upon induction with 1 mM IPTG under  
 5 optimal conditions, the transformed bacteria were able to produce 100-300  $\mu\text{g/ml}$  of the *ob* fusion. The majority of the *ob* fusion protein was found in the inclusion body. After solubilization with 6M guanidine-HCl or urea, the fusion protein was purified through a His-binding (Ni-chelation) resin column. The conditions for  
 10 column purification of the *ob* fusion protein (including binding, washing, and eluting) were established experimentally. The *ob* fusion protein binds to the resin at 5 mM imidazol/6M guanidine-HCl and stays bound at up to 20 mM imidazol/6M guanidine-HCl. The protein can be eluted from the resin at 60 mM imidazol/6M guanidine (Figure 18A,B). Both the purified human and mouse *ob* fusion proteins were further dialyzed in PBS to remove guanidine-HCl from the  
 15 preparation and used to raise polyclonal antibodies.

In order to test the biological activity of the fusion protein products, the refolding conditions for the purified protein was tested and developed. This involves initial dialysis of the fusion protein in 1 M guanidine solution, followed by dilution with 0.4 M arginine solution. The His-Tag was removed from the fusion proteins  
 20 before biological function assay. The tag removal was achieved by treating the fusion protein with thrombin from human placenta.

In addition, human and mouse *ob* gene coding sequence minus the signal sequence is being inserted into a pET 12c vector using PCR cloning method. These constructs can direct the synthesized *ob* fusion proteins into the periplasmic space  
 25 of the bacterial host cell. The *ob* fusion protein recovered from the periplasmic space may only need a simple gel filtration to be purified from other host proteins and will not be denatured during such process.

EXAMPLE: Preparation of Antibodies to the ob Polypeptide

In addition to use of the recombinant protein to generate polyclonal antibodies, a set of four peptide sequences from the deduced murine ob sequence were identified using immunogenicity plot software (GCG Package). The four carboxyl terminal  
5 peptide fragments are:

(SEQ ID NO:18):

Val-Pro-Ile-Gln-Lys-Val-Gln-Asp-Asp-Thr-Lys-Thr-Leu-Ile-Lys-Thr

(SEQ ID NO:19):

Leu-His-Pro-Ile-Leu-Ser-Leu-Ser-Lys-Met-Asp-Gln-Thr-Leu-Ala

10 (SEQ ID NO:20):

Ser-Lys-Ser-Cys-Ser-Leu-Pro-Gln-Thr-Ser-Gly-Leu-Gln-Lys-Pro-Glu-Ser-Leu-Asp

(SEQ ID NO:21):

Ser-Arg-Leu-Gln-Gly-Ser-Leu-Gln-Asp-Ile-Leu-Gln-Gln-Leu-Asp-Val-Ser-Pro-Glu-Cys

15 These peptides were conjugated to KLH, and the peptide-KLH conjugates were used to immunize rabbits using standard techniques. Polyclonal antisera specific for each peptide is recovered from the rabbits.

EXAMPLE: *In Vitro* Translocation of an ob Polypeptide

In order to confirm the presence of a functional signal sequence, a human cDNA  
20 that included the entire open reading frame was subcloned into the pGEM vector. Only the human cDNA was used in this experiment because suitable mouse subclones were not recovered. Positive strand human *ob* RNA was transcribed using sp6 polymerase and used in an *in vitro* translation reaction with and without canine pancreatic microsomal membranes. The primary translation product  
25 migrated with an apparent molecular weight of ~18 kD, which is consistent with that predicted by the cDNA sequence. Inclusion of the microsomal membranes in the reaction inhibited the overall efficiency of translation ~5 fold. Nevertheless,

approximately 50-70% of the *ob* primary translation product was truncated by approximately 2 kD in the presence of the membrane preparation, suggesting that the signal sequence is functional (Figure 19A). The size of the primary translation product of interleukin-1 $\alpha$  RNA, which does not encode a signal sequence, was  
 5 unchanged when microsomal membranes were included in the reaction. In order to confirm that translocation of the *ob* protein had taken place, the *in vitro* translation products were treated with Proteinase-K. Protease treatment resulted in the complete proteolysis of the 18 kD primary translation product while the 16 kD processed form was unaffected by the enzyme treatment, indicating that it had  
 10 translocated into the lumen of the microsomes (Figure 19B). These data are compatible with the hypothesis that *ob* is a secreted molecule.

After signal sequence cleavage, two cysteine residues would remain within the predicted protein raising the possibility that the molecule contains a disulfide bond characteristic of other secreted polypeptides (Shen and Rutter, 1984, Science  
 15 224:168-171).

#### EXAMPLE: Characterization of the *ob* Gene

To establish the relationship between obesity and genetic alterations in the *ob* gene in humans, the sequence of the human *ob* gene was determined (Figure 20A) (SEQ ID NO: ). Specific primers from the human coding sequence were used to screen  
 20 a human P1 library. Three different P1 clones were obtained, grown up, and PCR amplified using primers flanking the splicing site between the first and second coding exon. The entire intron region, around 2 kB, was amplified and partially sequenced (see Figure 20A; and as indicated in SEQ ID NO:22).

The gene structure of both the murine and human genes was characterized using  
 25 PCR assays and other standard techniques. The mouse *ob* gene was found to consist of 3 exons, the second and third of which account for the coding sequence

(Figure 20B). The coding region of the human *ob* gene shares the same structure; however, the human gene lacks a 5' exon and intron (Figure 20C).

Two sets of primers generated from the intronic sequences of the human gene have been prepared (Figure 20A). The sequences of the primers follows (F and R refer to forward and reverse, respectively):

HOB 1gF     5'-CCCAAGAAGCCCATCCTG-3' (SEQ ID NO:26)  
 HOB 1gR     5'-GACTATCTGGGTCCAGTGCC-3' (SEQ ID NO:27)  
 HOB 2gF     5'-CCACATGCTGAGCACTTGTT-3' (SEQ ID NO:28)  
 HOB 2gR     5'-CTTCAATCCTGGAGATACCTGG-3' (SEQ ID NO:29)

10 DNA samples have been obtained from various sources, and these sets of primers are being used to amplify human genomic DNA from severely obese people. The PCR products were run on a low melting point agarose gel, and the bands were cut out and digested with agarase. The sequences were obtained using the ABI 373A DNA sequencer and Taq dideoxy terminator kit (abi, Perkin-Elmer). One  
 15 point mutation in an *ob* gene from a patient sample has been detected to date. This mutation is on the first exon and does not change the amino acid sequence. Preliminary data indicate that an insertion sequence may be present in the first exon of another patient.

A different automated sequencing method with Sequenase instead of Taq DNA  
 20 polymerase may be employed to yield more easily readable sequences for mutation detection.

#### EXAMPLE: Expression of *ob* in Yeast

Following the positional cloning of *ob*, it became important to uncover the physiological mechanism by which the *ob* protein reduces food intake and body  
 25 weight. The first step in this direction was to recombinantly produce a functional



- protein using an expression system. In addition to the successful bacterial expression system, a yeast expression system was also selected. Yeast expression has several attractive features for expressing *ob*. The most important is that biologically active eukaryotic proteins are more likely to be produced. The ob polypeptide is secreted by mammalian cells. Protein secretion is very similar for all eukaryotes, which means that the yeast secretory apparatus is much more similar to the mammalian secretory pathway than bacterial secretory pathways would be. In particular, protein modifications of *ob* seen in mammalian cells would likely also be seen in the expression through the yeast secretory system. In addition, protein folding is carried out in passage through the secretory apparatus and thus delivering ob through the yeast secretory apparatus is likely to give a properly folded protein with native biological activity. This is significant for *ob* because the two cystein residues may form a disulfide bridge. In contrast to secretory pathways, the reducing environment of the cell cytoplasm prevents formation of disulfide bridges, and therefore it is essential that ob pass through the secretory pathway in order for this disulfide bond to form *in vivo*. Other advantages have to do with the ease and quickness of manipulating yeast, the availability of vectors and strains, and the vast experience in yeast recombinant technology.
- 20 A *Pichia pastoris* expression system was chosen for four reasons: (1) it has higher levels of heterologous protein expression than other yeast systems such as *S. cerevisiae*; (2) protein glycosylation is more similar to the mammalian system in *P. pastoris* than *S. cerevisiae* (although glycosylation sites were not detected in ob using a computer search, there still remained the possibility of glycosylation at unrecognized sites); (3) *P. pastoris* secretes very few proteins natively, and thus it is generally straightforward to purify the expressed foreign protein; and (4) the vectors and yeast strains are commercially available (from Invitrogen). Two strategies for generating yeast expression vectors are shown in Figures 21 and 22.

The vector chosen was pPIC.9. This vector contains a cloning site just downstream of the alpha-mating factor prepro coding sequence which directs the protein encoded by the gene cloned into the cloning site to be secreted by the secretory pathway. The other important feature of the vector is a HIS4 gene that

5 allows selection for uptake of the vector using a yeast auxotrophic strain grown on histidine-deficient media following transformation of the yeast with the vector. The cloning strategy was the following: PCR amplify *ob* cDNA using a 5' primer that contained at its 3' end sequence complementary to the sequence of *ob* just following the predicted leader peptide cleavage site, and at its most 5' end a

10 sequence complementary to the 3' end of the alpha-mating factor sequence of the vector. The 5' primer also contains an XhoI site. The 3' primer was designed to have at its 3' end a sequence complementary to the last few amino acids of *ob* and an EcoRI site at its 5' end. Following PCR amplification, the PCR product was digested with XhoI and EcoRI and cloned into similarly digested pPIC.9.

15 Following the cloning of both the mouse and human *ob* cDNAs, each with and without the glutamine at codon 49, individual clones were isolated for all four individual constructs and sequenced to verify that the constructs were cloned in the correct orientation and frame and contained no mutations from the PCR amplification step. Following identification of clones with the correct sequence,

20 these were transformed into *P. pastoris* strain GS115, a histidine auxotroph.

For the two mouse *ob* constructs, transformed yeast clones were screened for protein expression. As evidence that the transformed yeast contain *ob*, a DNA dot-blot assay and a colony hybridization assay were done which both showed *ob* sequence within the transformed yeast but not within the untransformed yeast.

25 Furthermore, the transformed yeast now secreted a 16 kDa protein into the culture media whereas the untransformed yeast does not secrete a protein of this size (Figure 23A). This is the predicted size of *ob*. Individual clones for both mouse constructs have been identified that are high expressors for *ob*, and currently a purification strategy is being developed to purify *ob* to homogeneity. One strategy

30 has been to purify *ob* on a cation exchange column (Figure 23B); preliminary data

suggest that a strong cation exchanger may be useful. However, after cation exchange chromatography, the putative ob product is lost. This indicates the presence of a protease in the sample.

One strategy to overcome this problem is to prepare *ob*-His tag fusions for expression in yeast (Figure 22). Further evaluation has demonstrated that *ob* without a His tag associates tightly with a Ni-chelation column. Purification of the ob polypeptide by Ni-chelation, followed by gel filtration, yielded a product of sufficient purity for mass spectral analysis. Mass spec confirms the molecular weight of the expressed protein is identical to the expected molecular weight, which strongly confirms that *ob* has been successfully expressed in *Pichia*.

However, the Ni-chelation/gel filtration purification protocol does not yield a ob polypeptide in sufficiently pure form. Additional small molecules are present. It does appear that the proteolytic activity elutes from the Ni-chelation column in the void volume. Accordingly, a three step purification process is planned: Ni-chelation, followed by cation exchange (which eliminates the small molecule contaminants), followed by gel filtration.

Estimating expression level by Coomassie blue staining of SDS-PAGE gels reveals approximately 10 mg/L when yeast are grown in shaker flasks. These levels are expected to increase in fermentation vessels, and we are about to initiate fermentation with the hopes of obtaining larger quantities of protein. Regarding the human *ob* constructs, transformed yeast clones containing high copy numbers of the *ob* gene have been identified, and these are expected to express ob protein. As antibodies are developed, these will be used to confirm the identity of the secreted 16 kDa protein.

Once purified the expressed protein is characterized by several methods. Physical characterization includes light-scattering to determine homogeneity of structure and is used as a measure of proper folding. Circular dichroism is used to roughly

determine the structural geometry of the protein. Importantly, bioactivity of the purified protein is assayed by administering the protein to both lean and obese rodents via an osmotic pump (*e.g.*, an ALZET osmotic pump from Alza Corporation, Palo Alto, CA) over at least a two-week period and observing effects on feeding behavior and body weight.

The following is a list of references related to the above disclosure and particularly to the experimental procedures and discussions.

- Bahary, N.; G. Zorich; J.D. Pachter; R. L. Leibel; and J.M. Friedman. 1991. Molecular genetic linkage maps of mouse chromosomes 4 and 6. Genomics 11:33-47.
- Bahary, N.; D. McGraw; R.L. Leibel; and J.M. Friedman. 1991. Chromosomal microdissection of midmouse chromosome 4: Mapping of microclones relative to the mouse *db* gene. Submitted.
- Bahary, N.; J. Pachter; R. Felman; R.L. Leibel; K.A. Albright; S. Cram; and J.M. Friedman. 1991. Molecular mapping of mouse chromosomes 4 and 6: Use of a flow-sorted Robertsonian chromosome. Submitted.
- Blank, R.; J. Eppig; F.T. Fiedorek; W.N. Frankel; J. M. Friedman; K. Huppi; I. Jackson; and B. Mock. 1991. Mouse chromosome 4. Mammalian Genome 1(suppl): s51-s78.
- Bogardus, C.; Ravussin, E.; Abbot, W.; Zsakzku, J.K.; Young, A.; Knowler, W.C.; Friedman, J.M.; R. L. Leibel; N. Bahary; D. A. Siegel; and G. Truett, G. 1991. Genetic analysis of complex disorders: Molecular mapping of obesity genes in mice and humans. Annals of the New York Academy of Sciences 630:100-115.

- Friedman, J.M.; R. L. Leibel; and N. Bahary. 1991. Molecular mapping of obesity genes. Mammalian Genome 1:130-144.
- Friedman, J.M.; R.L. Leibel; N. Bahary; and G. Zorich. 1991. Molecular mapping of the mouse *ob* mutation. Genomics, (in press).
- 5 Harris, M.I. (1991). *Diabetes Care* 14 (suppl. 3), 639-648.
- Harris, M.I.; Hadden, W.C.; Knowler, W.C.; and Bennett, P.H.(1987). *Diabetes* 36, 523-534.
- Harris, R.B.S. (1990). *FASEB J.* 4, 3310-3318.
- Jacobowitz, R., and Moll, P.O. (1986). *N. Engl. J. Med.* 315, 96-100
- 10 Kessey, R.E. (1980). In *Obesity*, A. Stunkard, eds. (Philadelphia: W.B. Saunders Co.), pp. 144-166.
- Kessey, R.E., and Pawley, T.L. (1986). *Annu. Rev. Psychol.* 37, 109-133.22
- Leibel, R.L., N. Bahary and J.M. Friedman. 1990. Genetic variation and nutrition in obesity: Approaches to the molecular genetics of obesity. In Genetic variation and Nutrition (Simopoulos, A.P. and Childs, B., eds.), S. Karger, Basel, pp. 90-101.
- 15 Siegel, D.; N.G. Irving; J.M. Friedman; and B. J. Wainwright. 1991. Localization of the cystic fibrosis transmembrane conductance regulator to mouse chromosome 6. Cytogenetics Cell Genetics, submitted.

Truett, G.E.; N. Bahary; J. M. Friedman; and R. L. Leibel. 1991. The rat obesity fatty (fa) maps to chromosome 5: Evidence for homology with the mouse gene diabetes (db). Proc. Natl. Acad. Sci. USA 88:7806-7809.

- This invention may be embodied in other forms or carried out in other ways
- 5 without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.
- 10 Various references are cited throughout this specification, each of which is incorporated herein by reference in its entirety.

0906647-101000

WHAT IS CLAIMED IS:

- 1 1. An isolated DNA molecule selected from the group consisting of:
  - 2 A. the DNA sequence of FIGURE 1 (SEQ ID NO:1);
  - 3 B. the DNA sequence of FIGURE 2 (SEQ ID NO:3);
  - 4 C. the DNA sequence of FIGURE 20A (SEQ ID NO:22);
  - 5 D. DNA sequences that hybridize to any of the foregoing DNA
  - 6 sequences under standard hybridization conditions;
  - 7 E. DNA sequences that code on expression for an amino acid sequence
  - 8 encoded by any of the foregoing DNA sequences;
  - 9 F. degenerate variants thereof;
  - 10 G. alleles thereof; and
  - 11 H. hybridizable fragments thereof.
- 1 2. An isolated nucleic acid molecule, which nucleic acid molecule encodes an  
2 ob polypeptide, which polypeptide is characterized by having about 145 to about  
3 167 amino acid residues, being expressed predominantly by adipocytes, and being  
4 capable of inducing a reduction of body weight in an animal.
- 1 3. The isolated nucleic acid of Claim 2, wherein the ob polypeptide has an  
2 amino acid sequence selected from the group consisting of the sequence depicted  
3 in Figure 1 (SEQ ID NO:2), Figure 1 from amino acid number 22 to amino acid  
4 number 167, Figure 3 (SEQ ID NO:4), Figure 3 from amino acid number 22 to  
5 amino acid number 167, Figure 5 (SEQ ID NO:5), Figure 5 from amino acid  
6 number 22 to amino acid number 166, Figure 6 (SEQ ID NO:6), and Figure 6  
7 from amino acid number 22 to amino acid number 166.
- 1 4. The nucleic acid molecule of Claim 2 selected from the group consisting of  
2 DNA and RNA.

- 1 5. The nucleic acid molecule of Claim 2, which has a sequence as shown in  
2 Figure 1 (SEQ ID NO:1) from nucleotide number 46 to nucleotide number 550.
- 1 6. The nucleic acid molecule of Claim 2, which has a sequence as shown in  
2 Figure 2 (SEQ ID NO:2) from nucleotide number 46 to nucleotide number 550.
- 1 7. The nucleic acid molecule of Claim 1 which is detectably labeled.
- 1 8. A cloning vector, which comprises the DNA molecule of Claim 1.
- 1 9. An expression vector, which comprises the nucleic acid molecule of Claim  
2 2, operatively associated with an expression control sequence.
- 1 10. The expression vector of Claim 9, wherein said expression control  
2 sequence is selected from the group consisting of the cytomegalovirus hCMV  
3 immediate early gene, the early or late promoters of SV40 or adenovirus, the lac  
4 system, the trp system, the TAC system, the TRC system, the major operator and  
5 promoter regions of phage  $\lambda$ , the control regions of fd coat protein, the promoter  
6 for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the  
7 promoters of the yeast  $\alpha$ -mating factors.
- 1 11. A probe capable of screening for a nucleic acid encoding an ob polypeptide  
2 in alternate species, which probe is a labeled DNA molecule of Claim 1.
- 1 12. A unicellular host transfected with a cloning vector of Claim 8.
- 1 13. A unicellular host transfected with an expression vector of Claim 9.
- 1 14. The unicellular host of Claim 13 wherein the unicellular host is selected  
2 from the group consisting of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, *Pichia*



1 15. An oligonucleotide primer for amplifying human genomic DNA encoding  
2 an ob polypeptide.

|   |         |  |
|---|---------|--|
| 3 | HOB 1gF | 5'-CCCAAGAAGCCCATCCTG-3' (SEQ ID NO:26)      |
| 4 | HOB 1gR | 5'-GACTATCTGGGTCCAGTGCC-3' (SEQ ID NO:27)    |
| 5 | HOB 2gF | 5'-CCACATGCTGAGCACTTGTT-3' (SEQ ID NO:28)    |
| 6 | HOB 2gR | 5'-CTTCAATCCTGGAGATACCTGG-3' (SEQ ID NO:29). |

1 18. An ob polypeptide, which polypeptide is characterized by having about 145  
2 to about 167 amino acid residues, being expressed predominantly by adipocytes,  
3 and being capable of inducing a reduction of body weight in an animal.

1 20. The ob polypeptide of Claim 19 which has the amino acid sequence shown  
2 in Figure 3 (SEQ ID NO:4) or Figure 6 (SEQ ID NO:6).

21. An immunogenic fragment of an ob polypeptide, which polypeptide is characterized by having about 160 amino acid residues, being expressed predominantly by adipocytes, and being capable of inducing a reduction of body weight in an animal.

1 23. A method for preparing an ob polypeptide comprising:  
2 A. culturing a unicellular host of Claim 12 or 13 under conditions that  
3 provide for expression of the ob polypeptide; and  
4 B. recovering the expressed ob polypeptide.

1 25. The method according to Claim 23, wherein the host cell is a yeast.

2 C. chromatographing the polypeptide on a Ni-chelation column; and  
3 D. purifying the polypeptide by gel filtration.

1 28. An antibody to the ob polypeptide of Claim 17.

1 29. An antibody to the ob polypeptide of Claim 18.

- 1 30. A method for preparing an antibody to an ob polypeptide, comprising:  
2 A. conjugating the immunogenic fragment of an ob polypeptide of  
3 Claim 19 to a carrier protein;  
4 B. immunizing a host animal with the ob polypeptide fragment-carrier  
5 protein conjugate of step A admixed with an adjuvant; and  
6 C. obtaining antibody from the immunized host animal.
- 1 31. An antibody to an ob polypeptide prepared according to a method  
2 comprising:  
3 A. conjugating an immunogenic fragment of an ob polypeptide of  
4 Claim 19 to a carrier protein;  
5 B. immunizing a host animal with the ob polypeptide fragment-carrier  
6 protein conjugate of step A admixed with an adjuvant; and  
7 C. obtaining antibody from the immunized host animal.
- 1 32. The antibody of Claim 28, 29, or 31 comprising a polyclonal antibody.
- 1 33. The antibody of Claim 28, 29, or 30 comprising a monoclonal antibody.
- 1 34. An immortal cell line that produces a monoclonal antibody according to  
2 Claim 33.
- 1 35. The antibody of Claim 28, 29, or 31 labeled with a detectable label.
- 1 36. The antibody of Claim 35 wherein the label is selected from the group  
2 consisting of enzymes, chemicals which fluoresce, and radioactive elements.
- 1 37. A method for measuring the presence of an ob polypeptide in a sample,  
2 comprising:  
3 A. contacting a sample suspected of containing an ob polypeptide with  
4 an antibody that binds to the ob polypeptide under conditions which allow for the

5 formation of reaction complexes comprising the antibody and the ob polypeptide,  
6 B. detecting the formation of reaction complexes comprising the  
7 antibody and ob polypeptide in the sample;  
8 in which detection of the formation of reaction complexes indicates the presence of  
9 ob polypeptide in the sample.

1 38. The method of Claim 37 in which the antibody is bound to a solid phase  
2 support.

1 39. The method of Claim 38 which further comprises contacting the sample  
2 with a labelled ob polypeptide step (A), and removing unbound substances prior to  
3 step (B), and in which the formation of reaction complexes in the sample is  
4 detected by observing a decrease in the amount of labelled ob polypeptide in the  
5 sample.

1 40. The method of Claim 38 which further comprises contacting the sample  
2 with a labelled antibody in step (A), which labelled antibody is an anti-ob  
3 polypeptide antibody, and removing unbound substances prior to step (B), and in  
4 which the formation of reaction complexes in the sample is detected by observing  
5 an increase in the amount of labelled antibody in the sample.

1 41. The method of Claim 37 in which an ob polypeptide is bound to a solid  
2 phase support.

1 42. The method of Claim 41 which further comprises contacting the sample  
2 with an ob polypeptide in step (A), and removing unbound substances prior to step  
3 (B), and in which the antibody is labelled and the formation of reaction complexes  
4 in the sample is detected by observing a decrease in the amount of labelled  
5 antibody.

1 43. A method for evaluating the level of ob polypeptide in a biological sample  
2 comprising

3 A. detecting the formation of reaction complexes in a biological sample  
4 according to the method of Claim 30; and

5 B. evaluating the amount of reaction complexes formed, which amount  
6 of reaction complexes corresponds to the level of ob polypeptide in the biological  
7 sample.

1 44. A method for detecting or diagnosing the presence of a disease associated  
2 with elevated or decreased levels of ob polypeptide in a mammalian subject  
3 comprising:

4 A. evaluating the level of ob polypeptide in a biological sample from a  
5 mammalian subject according to Claim 43; and

6 B. comparing the level detected in step (A) to a level of ob polypeptide  
7 present in normals or in the subject at an earlier time;  
8 in which an increase in the level of ob polypeptide as compared to normal levels  
9 indicates a disease associated with elevated levels of ob polypeptide, and decreased  
10 level of ob polypeptide as compared to normal levels indicates a disease associated  
11 with decreased levels of ob polypeptide.

1 45. A method for monitoring a therapeutic treatment of a disease associated  
2 with elevated or decreased levels of ob polypeptide in a mammalian subject  
3 comprising evaluating the levels of ob polypeptide in a series of biological samples  
4 obtained at different time points from a mammalian subject undergoing a  
5 therapeutic treatment for a disease associated with elevated or decreased levels of  
6 ob polypeptide according to the method of Claim 43.

1 46. The method according to Claim 44 or 45, wherein the disease associated  
2 with elevated levels of ob polypeptide is selected from the group consisting of  
3 AIDS, cachexia, cancer, and anorexia nervosa.

1 47. The method according to Claim 44 or 45, wherein the disease associated  
2 with decreased levels of ob polypeptide is selected from the group consisting of  
3 obesity, Type II diabetes, hypertension, and elevated blood lipids.

1 48. A test kit for measuring the presence or amount of ob polypeptide in a  
2 sample, comprising:

- 3 A. an anti-ob polypeptide antibody of Claim 28, 29, or 30;
- 4 B. means for detecting binding of the anti-ob polypeptide antibody to  
5 ob polypeptide in a sample;
- 6 C. other reagents; and
- 7 D. directions for use of the kit.

1 49. A method for changing the body weight of a mammal comprising inhibiting  
2 the expression of an ob polypeptide encoded by a nucleic acid of Claim 2.

1 50. The method according to Claim 49 comprising expressing an antisense  
2 nucleic acid molecule hybridizable to a nucleic acid that expresses the ob  
3 polypeptide, expressing a ribozyme that cleaves a nucleic acid that expresses the  
4 ob polypeptide, administering an antisense nucleic acid molecule hybridizable to a  
5 nucleic acid that expresses the ob polypeptide, and administering a ribozyme that  
6 cleaves a nucleic acid that expresses the ob polypeptide.

1 51. A pharmaceutical composition for reducing body weight of an animal  
2 comprising the ob polypeptide of Claim 17 and a pharmaceutically acceptable  
3 carrier.

1 52. A pharmaceutical composition for reducing body weight of an animal  
2 comprising the ob polypeptide of Claim 18 and a pharmaceutically acceptable  
3 carrier.

0938647 101000

1 53. A method for reducing the body weight of an animal comprising  
2 administering an amount of a pharmaceutical composition of Claim 52 effective to  
3 reduce the body weight of an animal to an animal believed to be in need of  
4 decreased body weight.

1 54. The method according to Claim 53 wherein the animal is a human, and the  
2 ob polypeptide is human ob polypeptide.

1 55. A method for reducing the body weight of a mammal comprising increasing  
2 the expression of a protein encoded by the nucleic acid of Claim 2.

1 56. A pharmaceutical composition for increasing the body weight of an animal  
2 comprising an antagonist of an ob polypeptide.

1 57. The pharmaceutical composition of Claim 56, wherein the antagonist is  
2 selected from the group consisting of an antibody that binds to and neutralizes the  
3 activity of ob polypeptide, a fragment of the ob polypeptide that binds to but does  
4 not activate the ob receptor, and a small molecule antagonist of the ob  
5 polypeptide.

1 58. A method for increasing the body weight of an animal comprising  
2 administering an amount of the pharmaceutical composition of Claim 56 effective  
3 to cause an increase in body weight to an animal believed to be in need of  
4 increased body weight.

ABSTRACT OF THE INVENTION

The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human *ob* gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question functions as a hormone. The present invention further provides nucleic acid molecules for use as molecular probes, or as primers for polymerase chain reaction (PCR) amplification, *i.e.*, synthetic or natural oligonucleotides. In further aspects, the present invention provides a cloning vector, which comprises the nucleic acids of the invention; and a bacterial, insect, or a mammalian expression vector, which comprises the nucleic acid molecules of the invention, operatively associated with an expression control sequence. Accordingly, the invention further relates to a bacterial or a mammalian cell transfected or transformed with an appropriate expression vector, and correspondingly, to the use of the above mentioned constructs in the preparation of the modulators of the invention. Also provided are antibodies to the *ob* polypeptide. Moreover, a method for modulating body weight of a mammal is provided. In specific examples, genes encoding two isoforms of both the murine and human *ob* polypeptides are provided.



[illegible]

Figure 2

---G--GTTG CAAGGCCCAA GAAGCCCA-- -TCCTGGGAA GGAAAATGCA 50  
TTGGGGAACC CTGTG-CGGA TTCTTGTGGC TTTGGCCCTA TCTTTTCTAT 100  
GTCCAAGCTG TGCCCATCCA AAAAGTCCAA GATGACACCA AAACCCCTCAT 150  
CAAGACAATT GTCACCAGGA TCAATGACAT TTCACACACG CAGTCAGTCT 200  
CCTCCAAACA GAAAGTCACC GGTTTGGACT TCATTCTTGG GCTCCACCCC 250  
ATCCTGACCT TATCCAAGAT GGACCAGACA CTGGCAGTCT ACCAACAGAT 300  
CCTCACCAGT ATGCCTTCCA GAAACGTGAT CCAAATATCC AACGACCTGG 350  
AGAACCTCCG GGATCTTCTT CACGTGCTGG CCTTCTCTAA GAGCTGCCAC 400  
TTGCCCTGGG CCAGTGGCCT GGAGACCTTG GACAGCCTGG GGGGTGTCCT 450  
GGAAGCTTCA GGCTACTCCA CAGAGGTGGT GGCCCTGAGC AGGCTGCAGG 500  
GGTCTCTGCA GGACATGCTG TGGCAGCTGG ACCTCAGCCC TGGGTGCTGA 550  
GGCCTTGAAG GTCACTCTTC CTGCAAGGAC T-ACGTTAAG GGAAGGAACT 600  
CTGGTTTCCA GGTATCTCCA GGATTGAAGA GCATTGCATG GACACCCCTT 650  
ATCCAGGACT CTGTCAATTT CCCTGACTCC TCTAAGCCAC TCTTCCAAAG 700  
G 701

09685647.101000

|       |             |            |            |            |            |     |
|-------|-------------|------------|------------|------------|------------|-----|
| Mouse | MCWRPLCRFL  | WLWSYLSYVQ | AVPIQKVQDD | TKTLIKTIVT | RINDISHTQS | 50  |
|       | * * * *     | * *        |            |            |            |     |
| Human | MHWGTLCGFL  | WLWPYLFYVQ | AVPIQKVQDD | TKTLIKTIVT | RINDISHTQS |     |
| Mouse | VSAQRVTGL   | DFIPGLHPIL | SLSKMDQTLA | VYQQVLTSLP | SONVLQIAND | 100 |
|       | *           |            | -          | -          | * *        |     |
| Human | VSSKQKVTGL  | DFIPGLHPIL | TLSKMDQTLA | VYQQILTSMP | SRNVIQISND |     |
| Mouse | LENLRDLLHL  | LAFSKSCSLP | QTSGLQKPES | LDGVLEASLY | STEVVALSRL | 150 |
|       | -           | *          | ** *-      | * *        |            |     |
| Human | LENLRDLLHV  | LAFSKSCHLP | WASGLETLDS | LGGVLEASGY | STEVVALSRL |     |
| Mouse | QGS LQDILQQ | LDV SPEC   |            |            |            | 167 |
|       | - *         | - *        |            |            |            |     |
| Human | QGS LQDMLWQ | LDLSPGC    |            |            |            |     |

Figure 5

1 Met Cys Trp Arg Pro Leu Cys Arg Phe Leu Trp Leu Trp Ser Tyr  
 16 Leu Ser Tyr Val Gln Ala Val Pro Ile Gln Lys Val Gln Asp Asp  
 31 Thr Lys Thr Leu Ile Lys Thr Ile Val Thr Arg Ile Asn Asp Ile  
 46 Ser His Thr Ser Val Ser Ala Lys Gln Arg Val Thr Gly Leu Asp  
 61 Phe Ile Pro Gly Leu His Pro Ile Leu Ser Leu Ser Lys Met Asp  
 76 Gln Thr Leu Ala Val Tyr Gln Gln Val Leu Thr Ser Leu Pro Ser  
 91 Gln Asn Val Leu Gln Ile Ala Asn Asp Leu Glu Asn Leu Arg Asp  
 106 Leu Leu His Leu Leu Ala Phe Ser Lys Ser Cys Ser Leu Pro Gln  
 121 Thr Ser Gly Leu Gln Lys Pro Glu Ser Leu Asp Gly Val Leu Glu  
 136 Ala Ser Leu Tyr Ser Thr Glu Val Val Ala Leu Ser Arg Leu Gln  
 151 Gly Ser Leu Gln Asp Ile Leu Gln Gln Leu Asp Val Ser Pro Glu  
 166 Cys End

00686647.101000

```

1 Met His Trp Gly Thr Leu Cys Gly Phe Leu Trp Leu Trp Pro Tyr
16 Leu Phe Tyr Val Gln Ala Val Pro Ile Gln Lys Val Gln Asp Asp
31 Thr Lys Thr Leu Ile Lys Thr Ile Val Thr Arg Ile Asn Asp Ile
46 Ser His Thr Ser Val Ser Ser Lys Gln Lys Val Thr Gly Leu Asp
61 Phe Ile Pro Gly Leu His Pro Ile Leu Thr Leu Ser Lys Met Asp
76 Gln Thr Leu Ala Val Tyr Gln Gln Ile Leu Thr Ser Met Pro Ser
91 Arg Asn Val Ile Gln Ile Ser Asn Asp Leu Glu Asn Leu Arg Asp
106 Leu Leu His Val Leu Ala Phe Ser Lys Ser Cys His Leu Pro Trp
121 Ala Ser Gly Leu Glu Thr Leu Asp Ser Leu Gly Gly Val Leu Glu
136 Ala Ser Gly Tyr Ser Thr Glu Val Val Ala Leu Ser Arg Leu Gln
151 Gly Ser Leu Gln Asp Met Leu Trp Gln Leu Asp Leu Ser Pro Gly
166 Cys End

```

Figure 7




Figure 8

0958547 101000







Figure 9



0938647-101000




```

+10      +20      +30      +40
1  GTGCAAGAAG AAGAAGATC CAGGGCAGGA AAATGTG CTG GAGACCCCTG
   CACGTTCTTC TTCTTCTAGG GTCCCCTCCT TTTACACGAC CTCTGGGGAC
   +10      +20      +30      +40
51 TGTGCGGTCC NGTGGNTTTG GTCCTATCTG TCTTATGTNC AAGCAGTGCC
   ACAGCCCAGG NCACCNAAAC CAGGATAGAC AGAATACANG TTCGTCAAGG
   +10      +20      +30      +40
101 TATCCAGAAA GTCCAGGATG ACACCAABAG CCTCATCAAG ACCATTGTCA
   ATAGGTCTTT CAGGTCCTAC TGTGGTTTTT GGAGTAGTTC TGGTAACAGT
   +10      +20      +30      +40
151 NCAGGATCAC TGANATTCA CACACG
   NGTCCTAGTG ACTNTAAAGT GTGTGC

```

Figure 11A



09685647 101000

Figure 11B

18S —

28S —



white fat

brain

small intestine

stomach

pancreas

lung

testis

heart

spleen

liver

09686647 101000

Figure 12 B





Figure 12 A



0968647 101000

Figure 13




Figure 14




Figure 15A







Figure 16



[illegible]

Figure 17





Figure 18 A



mM  
 soluble  
 insoluble  
 Flow thr.

imidazole  
 6 M Urea

5 mM  
 20 mM  
 60 mM  
 300 mM

Figure 19A





Figure 19B



0968647 101000

[illegible][illegible][illegible]



Figure 20B

MOUSE OB STRUCTURE





Figure 20c

HUMAN OB STRUCTURE



The diagram illustrates the cloning strategy for the *ob* gene into the pPIC9 vector. It shows the following steps:

- Initial DNA:** A linear DNA fragment containing the *ob* gene, flanked by XhoI and EcoRI sites. A signal sequence (SIG. SEQ.) is present at the N-terminus.
- PCR Amplification:** The DNA is amplified using PCR with high template concentration, cold cycling, and Pfu polymerase. This results in a PCR product with XhoI and EcoRI sites at the ends.
- Digestion:** The PCR product is digested with XhoI and EcoRI.
- Ligation:** The digested PCR product is ligated into the pPIC9 vector.
- pPIC9 Vector:** A circular plasmid vector containing the Amp<sup>r</sup> resistance gene, a 3' AOX promoter, a HIS4 gene, a TX TERM. SIGNAL, and a 5' AOX promoter.
- Final Construct:** The resulting recombinant plasmid (pPIC9-*ob*) is shown with the *ob* gene inserted between the 5' and 3' AOX promoters. The signal sequence is located upstream of the XhoI site.

Figure 21 B






Figure 21 c



The diagram illustrates a circular plasmid vector and a linear DNA fragment. The plasmid contains an origin of replication (ob), an ampicillin resistance gene (Amp<sup>r</sup>), a 3' AOX (arabinose operator) site, a HIS4 gene, and a TK TERM. SIGNAL. The linear DNA fragment has Xho I and EcoRI sites, a HIS-TAG, a THROMBIN CLEAVAGE SITE, and a MCS (multiple cloning site).

Figure 22B



0906047-101000

Figure 23A-




Figure 23B



|             |  |                         |
|-------------|--|-------------------------|
| APPLICANT:  | Friedman et al.  |                         |
| SERIAL NO.: | UNASSIGNED   | Group Art Unit: UNKNOWN |
| FILED:      | HEREWITH   | Examiner: UNKNOWN       |
| FOR:        | MODULATORS OF BODY WEIGHT, CORRESPONDING<br>NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC<br>AND THERAPEUTIC USES THEREOF |                         |

**ASSOCIATE POWER OF ATTORNEY**

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

The undersigned attorney for applicant hereby appoints Christine E. Dietzel, Ph.D., Registration No. 37,309, as Agent to prosecute the above-identified patent application and to transact all business in the Patent and Trademark Office connected therewith.

Please continue to address all correspondence as follows:

David A. Jackson, Esq.  
KLAUBER & JACKSON  
411 Hackensack Avenue  
Hackensack, New Jersey 07601

Respectfully submitted,

By:   
David A. Jackson, Esq.  
Attorney for Applicant  
Registration No. 26,742  
KLAUBER & JACKSON  
411 Hackensack Avenue  
Hackensack, NJ 07601  
(201)487-5800

Dated: October 10, 2000

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

As below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below under my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS  
AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC  
USES THEREOF**

the Specification of which

☒ is attached hereto  
☐ was filed on \_\_\_\_\_  
as Application Serial No. \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

| <u>APPLICATION</u><br><u>NUMBER</u> | <u>PRIOR FILED APPLICATION(S)</u><br><u>COUNTRY (DAY/MONTH/YEAR FILED)</u> | <u>PRIORITY</u><br><u>CLAIMED</u> |
|-------------------------------------|--|-----------------------------------|
| NONE                                |  |                                   |

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in any prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

| <u>APPLICATION</u><br><u>NO.</u> | <u>FILING DATE</u><br><u>(DAY/MONTH/YEAR)</u> | <u>STATUS - PATENTED, PENDING,</u><br><u>ABANDONED</u> |
|----------------------------------|---|--|
| 08/292,345                       | 17 August 1994                                | Pending  |



I hereby appoint as my attorneys or agents the following persons: Stefan J. Klauber (Attorney, Registration No. 22,604); David A. Jackson (Attorney, Registration No. 26,742); Barbara L. Renda (Attorney, Registration No. 27,626); Paul F. Fehlner (Agent, Registration No. 35,135); and Thomas E. Anderson (Agent, Registration No. 37,063), said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to:

DAVID A. JACKSON, ESQ.  
KLAUBER & JACKSON  
411 HACKENSACK AVENUE  
HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR:  
RESIDENCE:

JEFFREY M. FRIEDMAN  
500 East 63rd Street  
Apt. 17B  
New York, New York 10021  
U.S.A.  
Same

COUNTRY OF CITIZENSHIP:  
POST OFFICE ADDRESS:

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF SECOND JOINT INVENTOR:  
RESIDENCE:

YIYING ZHANG  
30 Waterside Place  
Apt. 27F  
New York, New York 10010  
PEOPLE'S REPUBLIC OF  
CHINA  
Same

COUNTRY OF CITIZENSHIP:

POST OFFICE ADDRESS:

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF THIRD JOINT INVENTOR: RICARDO PROENCA  
RESIDENCE: 26-62 30th Street  
Astoria, New York 11102  
COUNTRY OF CITIZENSHIP: U.S.A.  
POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF FOURTH JOINT INVENTOR: MARGHERITA MAFFEI  
RESIDENCE: 504 East 63rd Street  
Apt. 36S  
New York, New York 10021  
COUNTRY OF CITIZENSHIP: ITALY  
POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF FIFTH JOINT INVENTOR: JEFFREY L. HALAAS  
RESIDENCE: 420 East 70th Street  
Apt. 9J  
New York, New York 10021  
COUNTRY OF CITIZENSHIP: U.S.A.  
POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF FIFTH JOINT INVENTOR: KETAN GAJIWALA  
RESIDENCE: 500 East 63rd Street  
Apt. 11F  
New York, New York 10021  
COUNTRY OF CITIZENSHIP: INDIA  
POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

As below named inventors, we hereby declare that:

Our residence, post office address and citizenship are as stated below under our names.

We believe that we are the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF**

the Specification of which

☐ is attached hereto

☒ was filed on November 30, 1994

as Application Serial No. 08/347,563

and was amended on \_\_\_\_\_ (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

We hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

**PRIOR FILED APPLICATION(S)**

| <u>APPLICATION</u><br><u>NUMBER</u> | <u>COUNTRY</u> | <u>(DAY/MONTH/YEAR FILED)</u> | <u>PRIORITY</u><br><u>CLAIMED</u> |
|-------------------------------------|----------------|-------------------------------|-----------------------------------|
| N O N E                             |                |                               |                                   |

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in any prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

| APPLICATION<br>NO. | FILING DATE<br>(DAY/MONTH/YEAR) | STATUS - PATENTED, PENDING,<br>ABANDONED |
|--------------------|---------------------------------|--|
| 08/292,345         | 17 August 1994                  | PENDING                                  |

We hereby appoint as our attorneys or agents the following persons: Jack Matalon (Attorney, Registration No. 22,441); Stefan J. J. Klauber (Attorney, Registration No. 22,604); David A. Jackson (Attorney, Registration No. 26,742); Raymond M. Speer (Registration No. 26,810); Barbara L. Renda (Attorney, Registration No. 27,626); Paul F. Fehlner (Attorney, Registration No. 35,135); and Joseph M. Homa (Attorney, Registration No. P40,023), said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to:

DAVID A. JACKSON, ESQ.  
KLAUBER & JACKSON  
411 HACKENSACK AVENUE  
HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


FULL NAME OF FIRST INVENTOR: JEFFREY M. FRIEDMAN

RESIDENCE: 500 East 63rd Street  
Apt. 17B  
New York, New York 10021

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR



DATE February 20, 1996

FULL NAME OF SECOND JOINT INVENTOR: YIYING ZHANG

RESIDENCE: 1161 York Avenue, Apt. 7H  
New York, New York 10021

COUNTRY OF CITIZENSHIP: PEOPLE'S REPUBLIC OF CHINA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR *Yiying Zhang*

DATE February 23 1996

FULL NAME OF THIRD JOINT INVENTOR: RICARDO PROENCA

RESIDENCE: 26-62 30th Street  
Astoria, New York 11102

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF FOURTH JOINT INVENTOR: MARGHERITA MAFFEI

RESIDENCE: Via Trieste, 53  
56010 Asciano (Visa)  
ITALY

COUNTRY OF CITIZENSHIP: ITALY

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF FIFTH JOINT INVENTOR: JEFFREY L. HALAAS

RESIDENCE: 420 East 70th Street  
Apt. 9J  
New York, New York 10021

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR Jeffrey L. Halaas

DATE 2/20/96

FULL NAME OF SIXTH JOINT INVENTOR: KETAN GAJIWALA

RESIDENCE: 500 East 63rd Street  
Apt. 11F  
New York, New York 10021

COUNTRY OF CITIZENSHIP: INDIA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR K. Gajiwala

DATE 20 FEB 96

FULL NAME OF SEVENTH JOINT INVENTOR: STEPHEN K. BURLEY

RESIDENCE: 500 East 63rd Street  
Apt. 20A  
New York, New York 10021

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

As below named inventors, we hereby declare that:

Our residence, post office address and citizenship are as stated below under our names.

We believe that we are the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF**

the Specification of which

☐ is attached hereto

☒ was filed on November 30, 1994

as Application Serial No. 08/347,563

and was amended on \_\_\_\_\_ (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

We hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

| <u>APPLICATION</u> | <u>PRIOR FILED APPLICATION(S)</u>     | <u>PRIORITY</u> |
|--------------------|---------------------------------------|-----------------|
| <u>NUMBER</u>      | <u>COUNTRY (DAY/MONTH/YEAR FILED)</u> | <u>CLAIMED</u>  |
| N O N E            |                                       |                 |

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in any prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

| APPLICATION<br>NO. | FILING DATE<br>(DAY/MONTH/YEAR) | STATUS - PATENTED, PENDING,<br>ABANDONED |
|--------------------|---------------------------------|--|
| 08/292,345         | 17 August 1994                  | PENDING                                  |

We hereby appoint as our attorneys or agents the following persons: Jack Matalon (Attorney, Registration No. 22,441); Stefan J. J. Klauber (Attorney, Registration No. 22,604); David A. Jackson (Attorney, Registration No. 26,742); Raymond M. Speer (Registration No. 26,810); Barbara L. Renda (Attorney, Registration No. 27,626); Paul F. Fehlner (Attorney, Registration No. 35,135); and Joseph M. Homa (Attorney, Registration No. P40,023), said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to:

DAVID A. JACKSON, ESQ.  
KLAUBER & JACKSON  
411 HACKENSACK AVENUE  
HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR: JEFFREY M. FRIEDMAN

RESIDENCE: 500 East 63rd Street

Apt. 17B

New York, New York 10021

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_



FULL NAME OF SECOND JOINT INVENTOR: YIYING ZHANG  
RESIDENCE: 1161 York Avenue, Apt. 7H  
New York, New York 10021

COUNTRY OF CITIZENSHIP: PEOPLE'S REPUBLIC OF CHINA  
POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_  
DATE \_\_\_\_\_

FULL NAME OF THIRD JOINT INVENTOR: RICARDO PROENCA  
RESIDENCE: 26-62 30th Street  
Astoria, New York 11102

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA  
POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR *R. Proenca*  
DATE 2/19/96

FULL NAME OF FOURTH JOINT INVENTOR: MARGHERITA MAFFEI  
RESIDENCE: Via Trieste, 53  
56010 Asciano (Visa)  
ITALY

COUNTRY OF CITIZENSHIP: ITALY  
POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_  
DATE \_\_\_\_\_

FULL NAME OF FIFTH JOINT INVENTOR: JEFFREY L. HALAAS

RESIDENCE: 420 East 70th Street  
Apt. 9J  
New York, New York 10021

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF SIXTH JOINT INVENTOR: KETAN GAJIWALA

RESIDENCE: 500 East 63rd Street  
Apt. 11F  
New York, New York 10021

COUNTRY OF CITIZENSHIP: INDIA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF SEVENTH JOINT INVENTOR: STEPHEN K. BURLEY

RESIDENCE: 500 East 63rd Street  
Apt. 20A  
New York, New York 10021

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

As below named inventors, we hereby declare that:

Our residence, post office address and citizenship are as stated below under our names.

We believe that we are the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF**

the Specification of which

☐ is attached hereto

☒ was filed on November 30, 1994

as Application Serial No. 08/347,563

and was amended on \_\_\_\_\_ (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

We hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

| <u>APPLICATION</u> | <u>PRIOR FILED APPLICATION(S)</u>     | <u>PRIORITY</u> |
|--------------------|---------------------------------------|-----------------|
| <u>NUMBER</u>      | <u>COUNTRY (DAY/MONTH/YEAR FILED)</u> | <u>CLAIMED</u>  |
| N O N E            |                                       |                 |

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in any prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

09686647-101000

| APPLICATION<br>NO. | FILING DATE<br>(DAY/MONTH/YEAR) | STATUS - PATENTED, PENDING,<br>ABANDONED |
|--------------------|---------------------------------|--|
| 08/292,345         | 17 August 1994                  | PENDING                                  |

We hereby appoint as our attorneys or agents the following persons: Jack Matalon (Attorney, Registration No. 22,441); Stefan J. J. Klauber (Attorney, Registration No. 22,604); David A. Jackson (Attorney, Registration No. 26,742); Raymond M. Speer (Registration No. 26,810); Barbara L. Renda (Attorney, Registration No. 27,626); Paul F. Fehlner (Attorney, Registration No. 35,135); and Joseph M. Homa (Attorney, Registration No. P40,023), said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to:

DAVID A. JACKSON, ESQ.  
KLAUBER & JACKSON  
411 HACKENSACK AVENUE  
HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR: JEFFREY M. FRIEDMAN

RESIDENCE: 500 East 63rd Street  
Apt. 17B  
New York, New York 10021

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF SECOND JOINT INVENTOR: YIYING ZHANG

RESIDENCE: 1161 York Avenue, Apt. 7H  
New York, New York 10021

COUNTRY OF CITIZENSHIP: PEOPLE'S REPUBLIC OF CHINA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF THIRD JOINT INVENTOR: RICARDO PROENCA

RESIDENCE: 26-62 30th Street  
Astoria, New York 11102

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF FOURTH JOINT INVENTOR: MARGHERITA MAFFEI

RESIDENCE: Via Trieste, 53  
56010 Asciano (Visa)  
ITALY

COUNTRY OF CITIZENSHIP: ITALY

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF FIFTH JOINT INVENTOR: JEFFREY L. HALAAS

RESIDENCE: 420 East 70th Street  
Apt. 9J  
New York, New York 10021

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF SIXTH JOINT INVENTOR: KETAN GAJIWALA

RESIDENCE: 500 East 63rd Street  
Apt. 11F  
New York, New York 10021

COUNTRY OF CITIZENSHIP: INDIA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF SEVENTH JOINT INVENTOR: STEPHEN K. BURLEY

RESIDENCE: 500 East 63rd Street  
Apt. 20A  
New York, New York 10021

COUNTRY OF CITIZENSHIP: ~~UNITED STATES OF AMERICA~~ <sup>KING-DOM</sup>

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR SH B

DATE February 17, 1996

**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

As below named inventors, we hereby declare that:  
Our residence, post office address and citizenship are as stated below under our names.

We believe that we are the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**MODULATORS OF BODY WEIGHT, CORRESPONDING NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF**

the Specification of which

- ☐ is attached hereto  
☒ was filed on November 30, 1994  
as Application Serial No. 08/347,563  
and was amended on \_\_\_\_\_ (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

We hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

| <u>APPLICATION</u> | <u>PRIOR FILED APPLICATION(S)</u>     | <u>PRIORITY</u> |
|--------------------|---------------------------------------|-----------------|
| <u>NUMBER</u>      | <u>COUNTRY (DAY/MONTH/YEAR FILED)</u> | <u>CLAIMED</u>  |
| N O N E            |                                       |                 |

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in any prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a), which occurred between the filing date of the prior application and the national or PCT international filing date of this application:





FULL NAME OF SECOND JOINT INVENTOR: YIYING ZHANG

RESIDENCE: 1161 York Avenue, Apt. 7H  
New York, New York 10021

COUNTRY OF CITIZENSHIP: PEOPLE'S REPUBLIC OF CHINA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF THIRD JOINT INVENTOR: RICARDO PROENCA

RESIDENCE: 26-62 30th Street  
Astoria, New York 11102

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF FOURTH JOINT INVENTOR: MARGHERITA MAFFEI

RESIDENCE: Via Trieste, 53  
56010 Asciano (Pisa)  
ITALY

COUNTRY OF CITIZENSHIP: ITALY

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR Margherita Maffei

DATE 2/23/96

FULL NAME OF FIFTH JOINT INVENTOR: JEFFREY L. HALAAS

RESIDENCE: 420 East 70th Street  
Apt. 9J  
New York, New York 10021

COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF SIXTH JOINT INVENTOR: KETAN GAJIWALA

RESIDENCE: 500 East 63rd Street  
Apt. 11F  
New York, New York 10021

COUNTRY OF CITIZENSHIP: INDIA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

FULL NAME OF SEVENTH JOINT INVENTOR: STEPHEN K. BURLEY

RESIDENCE: 500 East 63rd Street  
Apt. 20A  
New York, New York 10021


COUNTRY OF CITIZENSHIP: UNITED STATES OF AMERICA

POST OFFICE ADDRESS: Same

SIGNATURE OF INVENTOR \_\_\_\_\_

DATE \_\_\_\_\_

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



SCANNED, # \_\_\_\_\_

Application deficiencies were found during scanning:

☒ Page(s) Fig 3 of Drawing were not present:  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present:  
for scanning. (Document title)

☐ Scanned copy is best available.